var title_f30_8_30848="Glaucoma Haab striae";
var content_f30_8_30848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Break in the basement (Descemet) membrane (Haab striae) secondary to corneal enlargement in congenital glaucoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a transverse break in Descemet membrane crossing the pupil. Note both edges of the break forming the appearance of railroad tracks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30848=[""].join("\n");
var outline_f30_8_30848=null;
var title_f30_8_30849="Endometrioma";
var content_f30_8_30849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of a left endometrioma in a patient with endometriosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30849=[""].join("\n");
var outline_f30_8_30849=null;
var title_f30_8_30850="Patient information: Antinuclear antibodies (The Basics)";
var content_f30_8_30850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/63/5106\">",
"         Patient information: Dermatomyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/59/9138\">",
"         Patient information: Polyarteritis nodosa (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/47/30450\">",
"         Patient information: Polymyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/23/28017\">",
"         Patient information: Scleroderma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/34/547\">",
"         Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/49/12051\">",
"         Patient information: Vasculitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/61/13265\">",
"         Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/11/26804\">",
"         Patient information: Myositis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/11/44212\">",
"         Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/22/44389\">",
"         Patient information: Vasculitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Antinuclear antibodies (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H82309607\">",
"      <span class=\"h1\">",
"       What are antinuclear antibodies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Antinuclear antibodies, called &ldquo;ANA&rdquo; for short, are proteins in the blood. They are made by the body&rsquo;s infection-fighting system, which is also called the immune system.",
"     </p>",
"     <p>",
"      Normally, a person&rsquo;s immune system makes antibodies when he or she gets an infection. The antibodies attack the germs causing the infection.",
"     </p>",
"     <p>",
"      If a person&rsquo;s immune system isn&rsquo;t working normally, it sometimes makes antibodies that attack his or her own body. This is called an autoimmune disease. Antibodies that attack a person&rsquo;s own body are also called autoantibodies. ANA are specific autoantibodies that attack substances inside of cells.",
"     </p>",
"     <p>",
"      Autoantibodies can damage different parts of the body, including the blood, skin, joints, kidneys, lungs, and nervous system.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H82309622\">",
"      <span class=\"h1\">",
"       What is an ANA test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ANA test is a blood test that measures the amount of ANA in your blood.",
"     </p>",
"     <p>",
"      A &ldquo;negative&rdquo; result means that you have no (or very little) ANA in your blood.",
"     </p>",
"     <p>",
"      A &ldquo;positive&rdquo; result means that you have ANA in your blood.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H82309637\">",
"      <span class=\"h1\">",
"       Why might a doctor or nurse order an ANA test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A doctor or nurse will order an ANA test to help figure out if you have an autoimmune disease. Many types of autoimmune diseases can cause a positive ANA test result. Some autoimmune diseases affect the whole body. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lupus",
"       </li>",
"       <li>",
"        Scleroderma",
"       </li>",
"       <li>",
"        Mixed connective tissue disease",
"       </li>",
"       <li>",
"        Polymyositis",
"       </li>",
"       <li>",
"        Dermatomyositis",
"       </li>",
"       <li>",
"        Rheumatoid arthritis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other autoimmune diseases affect only 1 part of the body, such as the thyroid (a gland in the neck), liver, or lungs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H82309652\">",
"      <span class=\"h1\">",
"       What does a negative ANA test result mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a negative result, you probably do NOT have an autoimmune disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H82309667\">",
"      <span class=\"h1\">",
"       What does a positive ANA test result mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a positive result, you might have an autoimmune disease.",
"     </p>",
"     <p>",
"      It&rsquo;s important to know that a positive result does not always mean a person has an autoimmune disease. Some people with a positive ANA result do not have an autoimmune disease and never get one. The higher the number (called the &ldquo;titer&rdquo;) of your ANA test, the greater the chance that you have an autoimmune disease.",
"     </p>",
"     <p>",
"      Also, some people with a positive ANA result do not have an autoimmune disease, but have an infection instead.",
"     </p>",
"     <p>",
"      To figure out whether you have an autoimmune disease, your doctor will also learn about your symptoms, do an exam, and order other lab tests. He or she might order blood tests that look for more specific autoantibodies. These can help your doctor figure out which type of autoimmune disease you might have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H82309682\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/63/5106?source=see_link\">",
"       Patient information: Dermatomyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/47/30450?source=see_link\">",
"       Patient information: Polymyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/23/28017?source=see_link\">",
"       Patient information: Scleroderma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/59/9138?source=see_link\">",
"       Patient information: Polyarteritis nodosa (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=see_link\">",
"       Patient information: Vasculitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/34/547?source=see_link\">",
"       Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=see_link\">",
"       Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=see_link\">",
"       Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/11/26804?source=see_link\">",
"       Patient information: Myositis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       Patient information: Vasculitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=see_link\">",
"       Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/8/30850?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86734 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30850=[""].join("\n");
var outline_f30_8_30850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309607\">",
"      What are antinuclear antibodies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309622\">",
"      What is an ANA test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309637\">",
"      Why might a doctor or nurse order an ANA test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309652\">",
"      What does a negative ANA test result mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309667\">",
"      What does a positive ANA test result mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82309682\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=related_link\">",
"      Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/63/5106?source=related_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/59/9138?source=related_link\">",
"      Patient information: Polyarteritis nodosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/47/30450?source=related_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/23/28017?source=related_link\">",
"      Patient information: Scleroderma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/34/547?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30851="Podophyllum resin: Drug information";
var content_f30_8_30851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Podophyllum resin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/10/44194?source=see_link\">",
"    see \"Podophyllum resin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Podocon-25&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Podofilm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Condylomata acuminatum:",
"     </b>",
"     Topical: Applied by physician only.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/10/44194?source=see_link\">",
"      see \"Podophyllum resin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Podocon-25&reg;: 25% (15 mL) [in benzoin tincture]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cleanse and dry affected area prior to application. Use applicator provided with product. When applying for the first time leave on for only 30-40 minutes to determine patient sensitivity. After first use may leave on 1-4 hours depending on severity of lesion; systemic absorption may occur with prolonged contact. Do not treat large areas or many warts at one time. Remove drug with alcohol or soap and water once treatment time has elapsed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of soft external genital (venereal) warts (condylomata acuminata); compound benzoin tincture generally is used as the medium for topical application",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, fever, polyneuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Paralytic ileus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Death",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not to be used on bleeding warts, birthmarks, moles, or warts with hair growth; not to be used by patients with diabetes or poor circulation; concurrent use of steroids; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use of large amounts of drug should be avoided. For external use only; avoid contact with the eyes as it can cause severe corneal damage; do not apply to moles, birthmarks, or unusual warts; do not use if wart or surrounding tissue is inflamed/irritated. To be applied by a physician only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reports in pregnant women have shown evidence of fetal abnormalities, fetal death, and stillbirth; use is contraindicated in women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Condiver (CO);",
"     </li>",
"     <li>",
"      Podoben (VE);",
"     </li>",
"     <li>",
"      Podofilia No. 2 (MX);",
"     </li>",
"     <li>",
"      Podofilm (CL, HK, SG);",
"     </li>",
"     <li>",
"      Podowart Paint (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly affects epithelial cell metabolism by arresting mitosis through binding to a protein subunit of spindle microtubules (tubulin)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;1993 Sexually Transmitted Diseases Treatment Guidelines,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1993, 42(RR-14):1-102.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30851/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfarb MT, Gupta AK, Gupta MA, et al, &ldquo;Office Therapy for Human Papillomavirus Infection in Nongenital Sites,&rdquo;",
"      <i>",
"       Dermatol Clin",
"      </i>",
"      , 1991, 9(2):287-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30851/abstract-text/1711941/pubmed\" id=\"1711941\" target=\"_blank\">",
"        1711941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9786 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30851=[""].join("\n");
var outline_f30_8_30851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210991\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210978\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210986\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210979\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210967\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210969\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210968\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210989\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210971\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210959\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299894\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293343\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210981\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210973\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210958\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/10/44194?source=related_link\">",
"      Podophyllum resin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30852="Severe rejection graft";
var content_f30_8_30852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe acute rejection of the ITx graft (high power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30852=[""].join("\n");
var outline_f30_8_30852=null;
var title_f30_8_30853="Reentry in AF";
var content_f30_8_30853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two types of reentry in atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The isochronal activation maps demonstrate two types of reentry in atrial fibrillation. Map A shows random reentry with three simultaneous wavefronts (black arrows) activating most of the recording area. Map B also shows three simultaneous wavefronts, but they are coming from different directions than those in map A. Maps C and D show two consecutive cycles of complete reentry. The wave of activation (black arrow) spreads clockwise in a circular fashion around a line of unexcited tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Holm M, Johansson R, Brandt J, et al. Eur Heart J 1997; 18:290.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30853=[""].join("\n");
var outline_f30_8_30853=null;
var title_f30_8_30854="Pegylated interferon (peginterferon) alfa-2b: Patient drug information";
var content_f30_8_30854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2b: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"     see \"Pegylated interferon (peginterferon) alfa-2b: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/12/38088?source=see_link\">",
"     see \"Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;;",
"     </li>",
"     <li>",
"      PegIntron&trade; Redipen&reg;;",
"     </li>",
"     <li>",
"      Sylatron&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Alpha interferons may cause or make diseases of the mind worse. Taking one's own life, ideas of killing yourself or murder, low mood (depression), forceful actions, hallucinations, psychoses, and relapse of drug addiction have happened with use. Alpha interferons may make infections worse, cause blood flow problems or some autoimmune diseases. If you think you have any of these health problems, call your doctor right away. Side effects such as low blood pressure, a fast heartbeat, and heart attacks have happened while taking alpha interferons. If you have very bad signs or if signs of these health problems get worse, talk with your doctor about stopping this drug. Problems are most often fixed after you stop the drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take with ribavirin if you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis C infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to peginterferon alfa-2b or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Autoimmune hepatitis or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count. This drug may need to be stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give the weekly shot at bedtime to lower the flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to give closely if you or a family member is giving the shot at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3424321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Hepatitis C infection:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with a drug called ribavirin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot is most often given once a week for a year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not getting better after 3 to 6 months of care, the drug is most often stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696493",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to time for your next dose, skip the missed dose and call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store vials at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store Redipen&reg; syringes in the refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right away after mixing or you may store in a refrigerator for up to 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened vial not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10952 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30854=[""].join("\n");
var outline_f30_8_30854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206967\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028861\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028863\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028862\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028867\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028868\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028870\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028865\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028866\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028871\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028872\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/12/38088?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30855="Evidence-based medicine and clinical trials in renal transplantation";
var content_f30_8_30855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evidence-based medicine and clinical trials in renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Rita R Alloway, PharmD, BCPS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Nicole A Pilch, PharmD, MSCR, BCPS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30855/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/8/30855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], there has been a dramatic increase in the number of successful renal transplants and use of non-cyclosporine immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/3-20\">",
"     3-20",
"    </a>",
"    ]. As the donor and recipient selection criteria for transplantation expand, in combination with the continued introduction of new immunosuppressive agents, the ability to identify the optimal immunosuppressive regimen for a given individual has grown increasingly complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/3-21\">",
"     3-21",
"    </a>",
"    ]. In addition, with improved graft and patient survival secondary to improved immunosuppression, trial outcome measures have also evolved, making individual trial results difficult to compare. To combat this difficulty, a critical, systematic, and scientific method for evaluating ongoing results from clinical trials is needed.",
"   </p>",
"   <p>",
"    Evidence-based medicine is the explicit and judicious use of current and best evidence to guide clinical decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Evidence-based medicine must be considered in the context of clinical expertise and with the understanding that its use is based on published literature, which is subject to reporting bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. Several guidelines for the publication and design of clinical trials in solid organ transplant recipients have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic provides an overview of the principles of evidence-based medicine in the evaluation of immunosuppressive regimens in renal transplantation. More general issues related to evidence-based medicine and decision analysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/22/14694?source=see_link\">",
"     \"Evidence-based medicine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22471?source=see_link\">",
"     \"Decision analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STUDY DESIGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized, double-blind, controlled clinical trials are the most appropriate design to prove the effectiveness of a new treatment. However, this design may not always be feasible or ethical in renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/23,28,29\">",
"     23,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the gold standard used to assess the efficacy of a new immunosuppressant agent alone or in combination was graft survival and the incidence of acute rejection, with the latter being a predictor for long-term graft survival. However, improvements in short and long-term allograft survival and the significant decrease in acute rejection rates have led researchers to alternative study designs and endpoints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, well-designed randomized, controlled clinical studies that specifically address questions regarding immunosuppressant or immunosuppressive agent combinations are still warranted in renal transplantation. With the explosion in the number of clinical trials evaluating immunosuppressive agents, meta-analyses have been used to address some of the limitations of these small and often underpowered clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. However, such analyses have inherent limitations, including study heterogeneity and non-specific or non-comparable endpoints and the inability to directly extrapolate findings to clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/24,34-36\">",
"     24,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analyses of data from large-scale databases such as the Scientific Registry of Transplant recipients (SRTR) and the United Network of Organ Sharing (UNOS) have also been performed to identify the optimal immunosuppressive regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Retrospective analyses of registry data are limited by the quality of the data, the various hidden sources of bias, and the inability to establish causal relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT POPULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When applying results from clinical trials to the individual transplant recipient, clinicians must consider several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type of transplant (deceased or living donor)",
"     </li>",
"     <li>",
"      Primary or repeat transplant",
"     </li>",
"     <li>",
"      Degree of sensitization (as reflected in the percentage of panel reactive antibody)",
"     </li>",
"     <li>",
"      Number of human leukocyte antigen (HLA) mismatches",
"     </li>",
"     <li>",
"      Ethnicity of the study population",
"     </li>",
"     <li>",
"      Cold ischemia time",
"     </li>",
"     <li>",
"      Incidence of delayed graft function",
"     </li>",
"     <li>",
"      Cause of recipient end-stage renal disease",
"     </li>",
"     <li>",
"      Peritransplant comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors can affect clinical outcomes such as acute allograft rejection, short- and long-term graft function, and graft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/20\">",
"     20",
"    </a>",
"    ]. Careful evaluation of these factors will provide the basis for employing results of clinical trials to the individual recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increasing number of immunosuppressive agents available, the number of available immunosuppression combinations has grown exponentially. Immunosuppression used in treatment and control groups should be comparable and current, so as to limit the introduction of systematic bias. As an example, a study comparing a regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    with a regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil would not be comparable because there is more than one difference between the treatment groups. In addition, concomitant agents that may influence surrogate endpoints, such as infection, should also be controlled. Thus, if the trial is evaluating two different maintenance immunosuppressive regimens, both study groups should receive the same type of induction therapy and concomitant prophylactic therapies. The transplant community has identified the need for unified definitions of infections following transplant, in an attempt to increase the external validity of trial results that use them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunosuppression regimen should include a description of the target dose, the target drug levels (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ), and the type of formulation used (Sandimmune&reg; or Neoral&reg;) to enable appropriate interpretation and extrapolation of results. More often, a trend toward a comparison of immunosuppressive regimens is described, rather than comparisons of the individual agents. Secondary to the importance of reporting and evaluating biomarkers of immunosuppressant efficacy, groups have published consensus reports discussing specific agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This trend is based upon the increasing number of immunosuppressant agents and the notable redundancy in the immune system necessitating the use of multiple agents with different mechanisms of action. Genetic variations in the pharmacokinetics and pharmacodynamics of immunosuppressant agents and subsequent responses have increased the awareness and need for \"patient specific or individualized\" immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant improvements in long-term renal allograft survival with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    has led investigators to focus more on optimizing long-term patient outcomes related to minimizing immunosuppressant exposure. These lower toxicity regimens are designed to either eliminate or reduce the toxicities of corticosteroids or calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/45\">",
"     45",
"    </a>",
"    ]. Examples of these regimens include corticosteroid free, avoidance, or early withdrawal regimens, and calcineurin inhibitor free, avoidance, or withdrawal regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY END POINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rejection, which may be variably defined as presumptive rejection, clinical rejection (treated but not biopsy-proven), or biopsy-proven rejection, has been the primary end point in most immunosuppressive drug trials. Thus, the definition of acute rejection must be clearly defined in the study, and the timing and treatment of such rejection episodes must be reported. In addition, the reporting of both biopsy- proven and clinical rejection frequencies is advocated to allow for comparison of results to other trials and for application of results to individual centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current regimens are associated with an incidence of acute rejection of less than 15 to 20 percent, decreased severity of the rejection, and a delay in the onset of acute rejection to beyond six months post-transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/4,11-15\">",
"     4,11-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .) Biopsy-proven acute rejection, at 12 months, has become recognized as one of the minimal criteria for end point determination and comparison.",
"   </p>",
"   <p>",
"    Since acute rejection rates with current immunosuppression are so low, it is difficult to design trials where enough patients obtain the statistical power needed to evaluate the outcome of interest. Various investigators have therefore recommended alternative and secondary end points. These include assessment of renal allograft function using biomarkers such as serum creatinine concentration, creatinine clearance, and cystatin C levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30,46,47\">",
"     30,46,47",
"    </a>",
"    ]. Other endpoints to help predict allograft survival include the use of renal allograft histology to determine the incidence of chronic allograft nephropathy, either through clinically indicated biopsy or on protocol surveillance biopsy; assessment of either immune activation or host accommodation; blood and urine immune markers or anti-donor specific HLA antibodies; and the toxicities of immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30\">",
"     30",
"    </a>",
"    ]. However, many of these surrogate markers are unproven, cost-prohibitive and lack adequate sensitivity and specificity for use in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30,48\">",
"     30,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient and allograft survival rates and the incidence of acute rejection remain the primary efficacy end points and the standard outcome needed to assess new immunosuppressant agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. It is necessary, however, that these end points be correlated with proven surrogate end points of long-term graft function in future clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, evaluation of composite end points has become more frequent. Composite end points were introduced to alleviate issues associated with the use of one single primary endpoint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Composite endpoints commonly used in renal transplant trials include a combination of the traditional end points (survival rates and acute rejection rates) or a combination of traditional end points with surrogate end points (such as renal function, histological findings, or markers of immune activation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUBGROUP ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subgroup analyses should be built into the study design prior to performance of the study to avoid the introduction of systematic bias. Even with proper design, definitive conclusions from subgroup analysis often cannot be made due to the small sample size of these clinical studies. However, if the treatment effect is substantial, then a subgroup analysis may be clinically relevant. Careful consideration of the statistical analysis must be used by both the investigator and reader to ensure appropriate interpretation of study results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POST HOC ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigators use post-hoc analysis to generate new hypotheses. A significant bias may exist unless these analyses are defined a priori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/26\">",
"     26",
"    </a>",
"    ]. Reporting of such analyses must clearly be defined as retrospective and include a description of the statistical analysis used to mitigate bias in the methods of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/26\">",
"     26",
"    </a>",
"    ]. Statistical limitations in post hoc analyses, however, should not underscore the importance of reporting clinically relevant end points necessary to ensure appropriate application of results, with the caveat that most studies are underpowered to detect differences in secondary end points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials should focus on the incidence and severity of relevant adverse events. Useful parameters for evaluating \"over\" immunosuppression include the incidence of opportunistic infection, and malignancy, such as posttransplant lymphoproliferative disorder (PTLD). Other common concerns are the incidence of posttransplant diabetes mellitus, anemia, hyperlipidemia, and gastrointestinal toxicities.",
"   </p>",
"   <p>",
"    The effects of adverse events upon cardiac function and adverse cardiovascular outcomes have also gained importance. There has been an increasing shift to allograft loss because of death, rather than the loss of an allograft secondary to loss function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each immunosuppressive agent has its own unique adverse events profile. When combinations are used, adverse events may be exaggerated when the toxicity profiles are similar, or may be attenuated when lower doses of each agent are used.",
"   </p>",
"   <p>",
"    Reporting of the incidence and listed rationale for participant withdrawal from clinical studies may also serve as an indirect indicator of the adverse event profile of an agent or regimens. Investigators should exercise caution when choosing the definition used to assess the incidence and severity of adverse effects in order to maintain end point generalizability and validity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REPORTING RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidated Standards of Reporting Trials (CONSORT) and the European Society of Transplantation (",
"    <a class=\"external\" href=\"file://www.esot.org/\">",
"     www.esot.org",
"    </a>",
"    ) have been proposed by investigators and editors to improve the quality and to standardize the reporting of clinical trial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The goal of these standards is to permit the reader to assess the validity of study results and compare results between trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the quality of publications of large multi-center clinical trials evaluating the immunosuppressive regimens in de novo renal transplant recipients was assessed there were considerable deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/22\">",
"     22",
"    </a>",
"    ]. Specifically, flaws in study design and publication reporting were identified, including a lack of follow up beyond the first 12 months post-transplantation. In addition, failure to delineate criteria used for the diagnosis of acute rejection and failure to describe use of censoring in reported graft survival rates was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations outlining the appropriate reporting of and assessment of multivariate regression analyses in the transplant literature were published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/54\">",
"     54",
"    </a>",
"    ]. This publication highlights the importance of reporting the modeling procedures as well as statistical tests to evaluate the validity of the model. Although the appropriate procedures are often performed they are not often reported secondary to lack of space, making appendices appropriate.",
"   </p>",
"   <p>",
"    Researchers and clinicians are urged to use CONSORT guidelines in reporting and interpretation of clinical trial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/43,52,53\">",
"     43,52,53",
"    </a>",
"    ]. Individual editorial boards are calling for adherence and use of these guidelines. Inability to provide the full description of trial protocols and analysis may influence publication of trial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30855/abstract/55\">",
"     55",
"    </a>",
"    ]. With the call for reporting uniformity, transplant clinicians must also urge the professional organizations and editorial boards to encourage the capture of all outcome related data. Limited funding in all research areas and small sample sizes halt reporting of non-statistically significant outcomes; however, to uncover clinically relevant applications, these data should be made available for pooled analysis, even when results are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the explosive increase in the number of different immunosuppressive agents, the ability to identify the optimal immunosuppressive regimen for a given individual remains unclear. In addition, lower acute rejection rates secondary to improved immunosuppression, trial outcome measures have also evolved, making individual trial results difficult to compare. To combat this difficulty, a critical, systematic, and scientific method for evaluating ongoing results from clinical trials is needed (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      When extrapolating results from clinical trials to the individual transplant recipient, clinicians must consider a large number of patient and regimen specific factors. These can affect clinical outcomes (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient population'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Comparable immunosuppressive regimens should be used in treatment and control groups (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunosuppressive regimen'",
"      </a>",
"      above). Acute rejection has been the primary end point in most immunosuppressive drug trials. However, since current acute rejection rates with current immunosuppression are so low, alternative and secondary end points have been recommended. These include the assessment of renal allograft function with surrogate measures such as serum creatinine concentration, creatinine clearance, or plasma cystatin C levels (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy end points'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Subgroup and post hoc analyses have been performed on trials evaluating kidney transplantation outcomes. There are major limitations with these types of analyses; however, they may provide novel hypotheses (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Subgroup analysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Post hoc analysis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Useful parameters for evaluating adverse events in patients administered immunosuppressive agents include the incidence of opportunistic infection, and malignancy, such as posttransplant lymphoproliferative disorder (PTLD). Other common concerns are the incidence of posttransplant diabetes mellitus, hyperlipidemia, and gastrointestinal toxicities (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse events'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Consolidated Standards of Reporting Trials (CONSORT) have been proposed by investigators and editors to improve the quality and to standardize the reporting of clinical trial results (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Reporting research'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/1\">",
"      Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/2\">",
"      A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/3\">",
"      Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/4\">",
"      Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/5\">",
"      Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/6\">",
"      Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/7\">",
"      Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/8\">",
"      Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/9\">",
"      A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/10\">",
"      Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/11\">",
"      Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/12\">",
"      Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/13\">",
"      Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/14\">",
"      Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/15\">",
"      Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/16\">",
"      Groth CG, B&auml;ckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/17\">",
"      Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/18\">",
"      MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/19\">",
"      Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.",
"     </a>",
"    </li>",
"    <li>",
"     Cecka, JM. The UNOS Scientific Renal Transplant Registry. In: Clinical Transplants 1998, Cecka, JM, Terasaki, PI (Eds), UCLA Tissue Typing Laboratory, Los Angeles 1998. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/21\">",
"      Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992; 268:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/22\">",
"      Fritsche L, Einecke G, Fleiner F, et al. Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant 2004; 4:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/23\">",
"      Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/24\">",
"      Garc&iacute;a L&oacute;pez FJ, Amen&aacute;bar Ir&iacute;bar JJ. The intricate relationship between evidence and clinical practice in kidney transplantation. J Nephrol 2000; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/25\">",
"      Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/26\">",
"      Budde K, Fritsche L. Proposal for guidelines for publication of randomized trials in the American Journal of Transplantation. Am J Transplant 2005; 5:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/27\">",
"      Fleiner F, Budde K, Dragun D, et al. Differences in reporting of acute rejections between American and European publications of large immunosuppressive trials impair comparability of study results. Transplant Proc 2005; 37:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/28\">",
"      Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/29\">",
"      Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/30\">",
"      Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003; 3:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/31\">",
"      Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/32\">",
"      Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/33\">",
"      Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/34\">",
"      Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/35\">",
"      Villar J, Carroli G, Beliz&aacute;n JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet 1995; 345:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/36\">",
"      Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996; 276:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/37\">",
"      Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/38\">",
"      Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/39\">",
"      Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant 2003; 3:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/40\">",
"      Hanto DW. Reliability of voluntary and compulsory databases and registries in the United States. Transplantation 2003; 75:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/41\">",
"      van der Meulen JH, Jacob M, Copley L. Assessing the quality of the data in a transplant registry: the European Liver Transplant Registry. Transplantation 2003; 75:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/42\">",
"      Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 1998; 279:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/43\">",
"      McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000; 283:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/44\">",
"      Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/45\">",
"      Lo A, Alloway RR. Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Pharmacotherapy 2002; 22:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/46\">",
"      Le Bricon T, Thervet E, Froissart M, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem 2000; 46:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/47\">",
"      Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 2006; 81:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/48\">",
"      Schold JD, Kaplan B. Design and analysis of clinical trials in transplantation: principles and pitfalls. Am J Transplant 2008; 8:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/49\">",
"      Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/50\">",
"      Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/51\">",
"      Teschner S, Geyer M, Wilpert J, et al. Remission of polyomavirus-induced graft nephropathy treated with low-dose leflunomide. Nephrol Dial Transplant 2006; 21:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/52\">",
"      Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY) 2005; 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     www.consort-statement.org (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/54\">",
"      Kalil AC, Mattei J, Florescu DF, et al. Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature. Am J Transplant 2010; 10:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30855/abstract/55\">",
"      Couser WG, Drueke TB, Halloran PF, et al. A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation. Am J Transplant 2005; 5:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7321 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30855=[""].join("\n");
var outline_f30_8_30855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STUDY DESIGN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT POPULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMMUNOSUPPRESSIVE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY END POINTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUBGROUP ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POST HOC ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REPORTING RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22471?source=related_link\">",
"      Decision analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/22/14694?source=related_link\">",
"      Evidence-based medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30856="Lymphangioleiomyomatosis CT I";
var content_f30_8_30856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69954%7EPULM%2F55093%7EPULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69954%7EPULM%2F55093%7EPULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangioleiomyomatosis in a 42-year-old woman. Multiple small cysts permeate the entire lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan demonstrates multiple thin-walled cystic airspaces of varying sizes, with loculated pneumothorax on the left (arrows) in a patient with pulmonary LAM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert S Crausman, MD and Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advanced lymphangioleiomyomatosis characterized by severe destruction of the lung parenchyma with replacement by cysts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30856=[""].join("\n");
var outline_f30_8_30856=null;
var title_f30_8_30857="Correcting excess anticoagulation after warfarin";
var content_f30_8_30857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Correcting excess anticoagulation after warfarin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Karen A Valentine, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/8/30857/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/8/30857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    has been the standard oral anticoagulant used in a variety of clinical settings; its clinical effect is monitored through a standardized prothrombin time, termed the International Normalized Ratio (INR). The optimal method for correcting excess anticoagulation after the use of warfarin (eg, returning an increased INR to the desired range) depends upon the degree of elevation and whether or not clinically significant bleeding is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], and will be discussed here.",
"   </p>",
"   <p>",
"    Management of intracerebral hemorrhage as a complication of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correction of excess anticoagulation in patients with prosthetic heart valves is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , including its biological properties, mechanism of action, laboratory monitoring, and complications is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    frequently become excessively anticoagulated, even those who have been stable for many months. The most common causes are interactions between warfarin and other drugs and superimposed diseases (eg, liver disease, malabsorption) that may interfere with warfarin ingestion, absorption, or metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"     \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should also be questioned about the number and size of the pills",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is taking, whether the prescription has been recently changed or renewed, and whether the color of the pills being prescribed is different from that usually taken, which may signify a difference in pill strength. When possible, the pills should be examined to make sure that the proper dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was being taken.",
"   </p>",
"   <p>",
"    Impaired cognition, depressed mood, and inadequate health literacy have been implicated in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    instability. This especially common in older patients, who should be reviewed regularly for the presence of, or development of, psychosocial defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Medical causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical causes of excessive levels of anticoagulation were reviewed in a study of 17,000 outpatients treated with oral anticoagulants in a regional Red Cross anticoagulation clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/5\">",
"     5",
"    </a>",
"    ]. An INR &ge;6.0 was noted on 22.5 per 10,000 treatment days. Factors significantly associated with an INR &ge;6.0 included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diarrhea &mdash; relative risk (RR) 12.8",
"     </li>",
"     <li>",
"      Worsened heart failure &mdash; RR 3.0 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fever &mdash; RR 2.9",
"     </li>",
"     <li>",
"      Impaired liver function &mdash; RR 2.8",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      rather than phenprocoumon &mdash; RR 1.9",
"     </li>",
"     <li>",
"      Stable heart failure &mdash; RR 1.6",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vitamin K deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficient are at risk for excessive degrees of anticoagulation following institution of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/7\">",
"     7",
"    </a>",
"    ]. This may result from poor dietary intake (eg, starvation, fasting, anorexia following chemotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    in the absence of vitamin K supplementation), vitamin K malabsorption (as in celiac disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/8\">",
"     8",
"    </a>",
"    ], or therapy with some antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"     \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link&amp;anchor=H18#H18\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Hematologic reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficiency is sufficiently severe, the INR may be prolonged even before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link&amp;anchor=H31#H31\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Prolonged PT and normal aPTT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Falsely elevated INRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of a falsely elevated INR is the presence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the blood sample. This can be avoided by obtaining the needed blood sample from a peripheral vein rather than from indwelling central venous catheters, which might be contaminated with heparin.",
"   </p>",
"   <p>",
"    Another common cause of a falsely elevated INR is inadequate filling of pediatric collection tubes, resulting in a higher than normal ratio of citrate anticoagulant to patient plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of coagulation tests\", section on 'Obtaining the sample'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very few randomized studies comparing the various treatment options for patients with an elevated INR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . This discussion outlines the available literature for each of the following scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     INR &lt;5 without bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the INR is above the therapeutic range but &lt;5.0 and no clinically significant bleeding is apparent, the next dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be omitted",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the maintenance dose of warfarin reduced. There is no need to reduce the dose of warfarin if the INR is only minimally prolonged (",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     INR 5 to 9 without bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the INR is between 5.0 and 9.0 and no clinically significant bleeding is present, the risk of a major hemorrhage within the next 30 days is estimated to be approximately 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/11\">",
"     11",
"    </a>",
"    ]. Two options are available for the correction of this degree of INR elevation: stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    temporarily, or stopping warfarin temporarily plus adding a small dose of ORAL",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"     table 1",
"    </a>",
"    ). However, even after correction of the INR, patients with a history of an INR &gt;4.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/12\">",
"     12",
"    </a>",
"    ], &gt;5.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/13\">",
"     13",
"    </a>",
"    ], or &gt;6.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/14\">",
"     14",
"    </a>",
"    ] were found to be at increased risk for future hemorrhage, especially those with an INR &gt;8",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    age &gt;70. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Stopping warfarin plus oral vitamin K'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Stopping warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next one to two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be withheld, the INR should be monitored more frequently, and a lower maintenance dose of warfarin should be reinstituted when the INR falls into the therapeutic range.",
"   </p>",
"   <p>",
"    A retrospective study reviewed the records of 633 patients with an index INR &gt;6.0, 80 percent of whom had been taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/15\">",
"     15",
"    </a>",
"    ]. In all cases, warfarin was withheld for two days, and a repeat INR was performed on the second day. Of the 562 patients with an index INR of 6 to 10, 34 percent were still excessively anticoagulated (INR &gt;4.0), while 12 percent of a group of 525 patients with an INR of 6 to 9 had a subtherapeutic INR (ie, INR &lt;2) on day two.",
"   </p>",
"   <p>",
"    A multiple logistic regression model indicated the following risk factors for having an INR &gt;4.0 on the second day:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Higher index INR",
"     </li>",
"     <li>",
"      Lower maintenance dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"     </li>",
"     <li>",
"      Active cancer",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, in patients with an index INR of 6 to 8, the risk of having an INR &gt;4 on day two was 14 percent for patients &lt;60 years old without heart failure or cancer, who were taking &ge;57.5 mg of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"      warfarin",
"     </a>",
"     /week.",
"    </span>",
"    The risk was 80 percent for patients &ge;80 years old with cancer or decompensated heart failure who were taking &ge;30",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"   </p>",
"   <p>",
"    In a second study, 114 patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least one month with an INR &gt;6.0 and no clinical bleeding were managed conservatively with temporary discontinuation of warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/16\">",
"     16",
"    </a>",
"    ]. Repeat INR was &lt;4.0 in 33, 55, 73, and 90 percent of patients after an interval of &lt;24, 48, 72, or 96 hours, respectively. Subsequent bleeding was noted in 10 of these patients (9 percent), with a major bleeding episode noted in 5 (4 percent), 2 of which were fatal.",
"   </p>",
"   <p>",
"    A similar study showed the safety of this approach in 26 children who were taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and had an INR &ge;5.0 (mean INR 5.9) without bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/17\">",
"     17",
"    </a>",
"    ]. The mean INR one day after withholding one dose of warfarin was 3.3 (range 1.2 to 6.8), with 89 percent of the INR values falling below 5.0. There were no overt bleeding or symptomatic thrombotic events in the following month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stopping warfarin plus oral vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach in patients with an INR between 5 and 9 and no bleeding, especially in those at increased risk for bleeding, consists of withholding the next dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and administering 1 to 2.5 mg of",
"    <strong>",
"     oral",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    , which corrects the excessive degree of anticoagulation more rapidly than the simple withholding of warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/12,18\">",
"     12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such small doses are effective for reducing the INR quickly into the therapeutic range, while larger doses tend to lower a moderately elevated INR into the normal range and render the patient temporarily resistant (eg, days to weeks) to further therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A lower maintenance dose of warfarin should be reinstituted when the INR falls into the therapeutic range (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Stopping warfarin'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The safety and efficacy of this approach were confirmed in a randomized, double-blind trial, in which 724 asymptomatic patients with an INR between 4.5 and 10 had their",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose withheld and were randomly assigned to receive either 1.5 mg of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    or matching placebo. The following results were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An INR in the range of 2.0 to 3.0 on the day after treatment was significantly less common in the placebo group (10 versus 42 percent).",
"     </li>",
"     <li>",
"      At 90 days after intervention, the cumulative incidences of thromboembolism, major bleeding, or any bleeding were 1.0, 1.8 and 16 percent, respectively, with no significant difference between the two treatment arms.",
"     </li>",
"     <li>",
"      Of the 13 major bleeding events reported in the study, 10 (77 percent) occurred in subjects &gt;70 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Route of vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 10 randomized and 11 prospective trials was performed to determine the relative effectiveness of the various routes of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    administration for improving the INR in patients overanticoagulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to an INR of 4.0 to 10.0 without bleeding. The percentages of patients with an INR in the range of 1.8 to 4.0 twenty-four hours after stopping warfarin and the administration of vitamin K by various routes were, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Placebo &mdash; 20 percent (95% CI 0-47)",
"     </li>",
"     <li>",
"      Subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      &mdash; 31 percent (95% CI 7-55)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      &mdash; 77 percent (95% CI 60-95)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      &mdash; 82 percent (95% CI 70-93)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the subcutaneous route for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    was no better for this purpose than placebo, and should not be employed. Since the oral and intravenous routes were equally effective, and there is a risk of anaphylaxis with the intravenous route, the oral route is to be preferred.",
"   </p>",
"   <p>",
"    This analysis was unable to determine the optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    ; effective doses ranged from 1.0 to 2.5 and 0.5 to 3.0 mg for the oral and intravenous routes, respectively. Given the size of vitamin K tablets available in the United States (5.0 mg, scored to allow administration of 2.5 mg), it has been suggested that a 1.0 mg oral dose is most reliably given by administering 1.0 mg of the intravenous preparation (2.0",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    by mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acenocoumarol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    to stopping anticoagulation may not be necessary in patients overanticoagulated (ie, INR 4 to 10 without bleeding) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , a coumarin derivative widely used in Europe and other countries, which has a shorter half-life than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/3,24,25\">",
"     3,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     INR &gt;9 without bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the INR is &gt;9.0 and the patient is without clinically significant bleeding,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be stopped and 2.5 to 5 mg of",
"    <strong>",
"     oral",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    administered, which should produce a substantial reduction in the INR within 24 to 48 hours (",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. The INR should be monitored closely, and repeat treatment with oral vitamin K should be undertaken as necessary. A reduced maintenance dose of warfarin should be restarted when the INR falls into the therapeutic range.",
"   </p>",
"   <p>",
"    As noted above, it has been suggested that these oral doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    may be reliably given by administering the intravenous preparation (2.0",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    <strong>",
"     by mouth",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elevated INR with minimal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little in the way of guidance as to how patients with an elevated INR (eg, &gt;5) with only minimal bleeding should be treated. Such patients can be treated as outlined above (ie, INR &gt;9 without bleeding), or as outlined below for those with significant bleeding. The choice of approach is based largely on clinical judgment, the current level of the INR, the percent of time the patient has been supra-therapeutic over the past month or so, the current extent of bleeding, and the risk of worsening of the bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H33#H33\">",
"     \"Therapeutic use of warfarin\", section on 'Other causes for bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Significant or life-threatening bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid reversal of excessive anticoagulation should be undertaken in patients with serious bleeding at any degree of anticoagulation (",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1,29,30\">",
"     1,29,30",
"    </a>",
"    ]. General measures that should be taken in any patient with anticoagulant-associated severe bleeding are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H32#H32\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Emergency treatment of bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If serious or life-threatening bleeding is present, or if rapid reversal of anticoagulation is required (eg, in preparation for emergency surgery),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be stopped and 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    administered by a",
"    <strong>",
"     slow intravenous",
"    </strong>",
"    infusion (eg, over 20 to 60 minutes), supplemented by transfusions of fresh frozen plasma (FFP, initial dose: 2 to 3 units; more as clinically indicated) for less urgent situations. For more urgent situations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    or prothrombin complex concentrate (PCC) may be employed. Suggested doses of recombinant factor VIIa to use in this setting are unclear, but have been in the range of 10 to 80",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Recombinant factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suggestions for how this should be accomplished with FFP or PCC include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the desired target INR, as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Moderate bleeding and high thrombotic risk: target INR 2.0 to 2.1",
"     </li>",
"     <li>",
"      Serious bleeding and moderate thrombotic risk: target INR 1.5",
"     </li>",
"     <li>",
"      Serious or life-threatening bleeding and low thrombotic risk: target INR 1.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the approximate prothrombin complex percentage according to the INR:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      INR &ge;4.0: 5 to 10 percent of normal activity",
"     </li>",
"     <li>",
"      INR 1.9 to 3.2: 15 to 25 percent of normal activity",
"     </li>",
"     <li>",
"      INR 1.4 to 1.8: 30 to 40 percent of normal activity",
"     </li>",
"     <li>",
"      INR 1.0: 100 percent of normal activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the dose of FFP or PCC from the following formula:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dose = (target INR level [as %] &ndash; present INR level [as %]) x body weight (kg)",
"     </li>",
"     <li>",
"      This is the mL of FFP or the International Units of PCC needed",
"     </li>",
"     <li>",
"      As an example, in a 70 kg patient with a pulmonary embolus 3 months prior who now has major intestinal bleeding and an INR of 7.5 (5 percent of normal activity), the target INR would be 1.5 (40 percent of normal activity), and the dose would be: (40 &ndash; 5) x 70 = 2450 mL of FFP or 2450 International Units of PCC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The INR should be monitored frequently.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    may be repeated at 12-hour intervals. Fresh frozen plasma (FFP), PCC, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    can be repeated if necessary, depending upon the INR response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of this combined approach was illustrated in a report of 10 patients with major bleeding and an INR &ge;8.0 (range 8.9 to &gt;20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients were treated with a single intravenous dose of 5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    and 30",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    of PCC (Beriplex",
"    <span class=\"nowrap\">",
"     P/N)",
"    </span>",
"    infused over a 10 to 15 minute period. The median INR 30 minutes post-treatment was 1.1 (range: 1.0 to 1.3). Once treatment was given there was no further evidence of fresh bleeding, no thromboembolic complications, and no adverse events.",
"   </p>",
"   <p>",
"    Similar efficacy was seen two other studies in a total of 86 patients requiring immediate reversal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for any cause (eg, severe bleeding or preparation for emergency surgery or interventional procedures) who had somewhat lower initial INR levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two separate studies involving a total of 17 patients, doses of recombinant factor VIIa (NovoSeven) as low as 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV were successfully and safely used in patients in whom excessive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated bleeding was present",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapid reduction of anticoagulation was required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Use of this agent avoids the need for large volumes of fresh-frozen plasma in patients at risk for volume overload.",
"   </p>",
"   <p>",
"    Both PCC products and recombinant factor VIIa may be unavailable for acute reversal of overanticoagulation in some medical centers in the United States and Europe and their high expense (and off-label status of the latter) pose serious constraints on their use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, the PCC products available in the United States (but not those available in Canada and Europe), the so-called \"three-factor\" PCCs, may have low concentrations of factor VII, requiring additional use of FFP to effectively lower an elevated INR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Regulatory concerns and costs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of intracerebral hemorrhage as a complication of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correction of excess anticoagulation in patients with prosthetic heart valves is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Superwarfarin poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"superwarfarins\" (brodifacoum, bromadiolone, coumafuryl, difenacoum) are lipophilic, long-acting rat poisons (rodenticides), which are up to 100 times as potent as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . They have half-lives within the body on the order of weeks to months, as compared with 40 hours for warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poisoning with superwarfarins has been due to accidental exposure and suicide attempts, as well as occupational exposure. Subjects may also be exposed when drugs of abuse (eg, marijuana, crack cocaine) are laced with superwarfarins, presumably to potentiate their effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subjects poisoned with one of the superwarfarins may present with bleeding and prolonged PT, aPTT, and INR, and usually require",
"    <strong>",
"     massive",
"    </strong>",
"    doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    (eg, 50 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) given over extended periods of time (eg, months) in order to control their coagulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/39-41,44\">",
"     39-41,44",
"    </a>",
"    ]. The diagnosis is confirmed when specific assays for the superwarfarin molecule are performed. Repeated assays may be helpful in determining the duration of vitamin K treatment required in a particular individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/40,44\">",
"     40,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21790898\">",
"    <span class=\"h2\">",
"     Vitamin K formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    represents a family of structurally similar compounds required for the synthesis of vitamin K-dependent clotting factors. Commercially available preparations include vitamin K1 (phytonadione, the form produced by plants), K2 (menaquinone, the form synthesized by bacteria and mitochondria, and the main storage form in humans), and other synthetic forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Most of the clinical trials that have studied vitamin K administration for treatment of coagulopathy have used vitamin K1, and this is the most commonly available formulation in the United States. Since both vitamin K1 and K2 are effective in reversing coagulopathy, we favor whichever formulation is most readily available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HEAD TRAUMA AND INTRACRANIAL BLEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21790994\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been recommended that unanticoagulated patients with mild head injury (low-risk group: those who are asymptomatic or who have one or more of the following: headache, dizziness, scalp hematoma, laceration, contusion, or abrasion) are unlikely to have associated intracranial injury, and that CT scanning is not required in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/47\">",
"     47",
"    </a>",
"    ]. Whether this is true for low-risk patients who are anticoagulated is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Two retrospective studies shed some light on this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated patients receiving anticoagulation who presented to two different accident and emergency departments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/50\">",
"       50",
"      </a>",
"      ]. Patients were included if they would otherwise have been judged as low-risk and had a CT scan performed. A total of 144 patients met inclusion criteria; most were elderly women taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for atrial fibrillation who had suffered a fall. The incidence of significant CT findings (ie, one resulting in a change in the patient's care) was 7 percent (95 percent confidence limits: 3 to 11 percent), similar to that in non-anticoagulated patients with moderate-risk trauma (ie, those presenting with post-traumatic amnesia, seizures, vomiting, unreliable histories, or multiple trauma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review determined the incidence of intracranial hemorrhage (ICH) in 141 patients with minor head trauma who were taking anticoagulant or antiplatelet medication, had a Glasgow Coma Scale of 15 (the best possible score, consistent with mild brain injury (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 2",
"      </a>",
"      )), and underwent head CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/51\">",
"       51",
"      </a>",
"      ]. In this study, 41 (29 percent) were diagnosed with ICH, 5 required surgical evacuation of an ICH, and 4 died. Loss of consciousness predicted for a positive CT result, while the type of medication (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) did not reach statistical significance as a predictor of a positive result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that intracranial imaging should be performed during emergency assessment of head trauma in all patients receiving anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21791001\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of intracranial hemorrhage in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGERY/INVASIVE PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, it is necessary to temporarily reverse chronic anticoagulation in order to prepare the patient for an invasive procedure. In these cases, a small dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    administered slowly by intravenous infusion may be most appropriate. Two studies have evaluated the appropriate dose of vitamin K to be used in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study of 105 chronically anticoagulated patients being prepared for surgery or an invasive procedure, most subjects stopped",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and received a single 0.5 to 1.0 mg dose of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/53\">",
"       53",
"      </a>",
"      ]. This resulted in an INR of 1.4 or less in 57 percent of the patients at a median elapsed time of 27 hours. There were no episodes of thromboembolism, while procedure-associated major bleeding was noted in 2.4 percent of patients. Warfarin was reinstituted on the day following the procedure or surgery, with a median elapsed time from procedure completion to an INR &ge;2.0 of 4.1 days.",
"     </li>",
"     <li>",
"      In a prospective single-arm study, 178 patients on long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy stopped this treatment and received 3 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      12 to 18 hours prior to elective surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/54\">",
"       54",
"      </a>",
"      ]. An INR &le;1.7 or &le;1.4 was achieved in 100 and 94 percent of the subjects on the day of surgery. Warfarin was re-started within 12 to 24 hours post-procedure at the previous therapeutic dose. Four patients (2.2 percent) had procedure-related major bleeding, although all four had an INR &lt;1.5 and vitamin K-dependent factor levels &gt;0.30 International",
"      <span class=\"nowrap\">",
"       Units/mL",
"      </span>",
"      at the time of the bleeding episode. No patient had an adverse reaction to the vitamin K infusion or a symptomatic thromboembolism during a six-week follow-up period. A therapeutic INR was re-established at a median time of four days post-procedure (range: 2 to 11 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that the 3 mg dose achieved preoperative INR goals better than the 0.5 to 1 mg dose, with no more in the way of side effects, bleeding, thromboembolism, or time to reestablish a therapeutic INR, we prefer the 3 mg dose for this purpose.",
"   </p>",
"   <p>",
"    Management of anticoagulation before and after elective surgery, gastroenterologic procedures, or in patients with prosthetic valves is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Reversing the vitamin K antagonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=see_link\">",
"     \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9418662\">",
"    <span class=\"h1\">",
"     ACCP GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate recommendations for the correction of excessive anticoagulation with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists are more consistent with the 2008 American College of Chest Physicians (ACCP) clinical practice guidelines (",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1\">",
"     1",
"    </a>",
"    ] than the 2012 ACCP guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/8/30857/abstract/55\">",
"     55",
"    </a>",
"    ]. The latter differ in that some of their prior recommendations are now suggestions based on moderate to low quality evidence. As examples of the two major changes in the 2012 ACCP Guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       INR between 4.5 and 10 without bleeding",
"      </strong>",
"      &mdash; The 2012 ACCP guidelines suggest against the routine use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      in this setting (moderate quality evidence) whereas the 2008 guidelines suggested its use, particularly if the patient is at an increased risk of bleeding (high quality evidence).",
"     </li>",
"     <li>",
"      <strong>",
"       Major bleeding",
"      </strong>",
"      &mdash; The 2012 ACCP guidelines suggest rapid reversal of anticoagulation with",
"      <strong>",
"       four-factor",
"      </strong>",
"      prothrombin complex concentrate (PCC) rather than with plasma (low quality evidence) plus the use of 5 to 10 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (low quality evidence). The 2008 guidelines recommended the use of 10 mg of intravenous vitamin K supplemented with either fresh frozen plasma, PCC, or recombinant factor VIIa, depending on the urgency of the situation. In this regard it should be noted that four-factor PCC products are currently unavailable in the United States, but are available in Canada and Europe. So-called three-factor PCC products, which contain suboptimal concentrations of factor VII, are the only PCC products available in the United States. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Unactivated prothrombin-complex concentrates'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overanticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , requiring action on the part of the clinician, is present when one or both of the following occur:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The patient has a standardized prothrombin time test result (the International Normalized Ratio, INR) which is greater than the upper limit of the targeted INR range (eg, an INR &gt;3.0 in a non-bleeding patient whose INR target range is 2.0 to 3.0).",
"     </li>",
"     <li>",
"      The patient develops clinically significant bleeding, irrespective of the degree of elevation of the INR (eg, an episode of massive retroperitoneal bleeding in a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -treated patient with an INR of 2.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of overanticoagulation include interaction with another medication, wrong dosage of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      deficiency, diarrhea, heart failure, fever, and impaired liver function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Occasionally, a patient will have a variable and unstable response to warfarin over a period of time, which cannot be attributed to one or more of the above causes. This subject, and its management, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with high doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      may make it difficult to resume effective anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for days to weeks after the episode has been controlled. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Stopping warfarin plus oral vitamin K'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an",
"      <strong>",
"       INR &lt;5 and no bleeding",
"      </strong>",
"      , we recommend either lowering the subsequent dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or omitting one or more doses of warfarin. The INR should then be monitored more frequently, and therapy resumed at an adjusted dose when the INR is again within the desired target range (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If the INR elevation is minimal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      expected to be transient, no dose reduction may be necessary. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'INR &lt;5 without bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an",
"      <strong>",
"       INR of 5 to 9 without bleeding",
"      </strong>",
"      , we recommend omitting a dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and administering a low dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (eg, 1 to 2.5 mg), given orally, rather than by the subcutaneous or intravenous route (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The INR should then be monitored more frequently, and therapy resumed at a reduced dose once the INR is again in the therapeutic range. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'INR 5 to 9 without bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If more rapid reversal is required because of the need for",
"      <strong>",
"       urgent surgery",
"      </strong>",
"      , we suggest stopping",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and administering one or more oral doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (&le;5",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgery/invasive procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an",
"      <strong>",
"       INR &ge;9 without bleeding",
"      </strong>",
"      , we recommend holding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, administering one or more 2.5 to 5 mg doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      <strong>",
"       orally",
"      </strong>",
"      , monitoring the INR more frequently, and resuming therapy at a reduced dose once the INR is again in the therapeutic range, rather than more aggressive treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       serious or life-threatening bleeding and any degree of anticoagulation,",
"      </strong>",
"      we recommend holding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and giving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (10 mg) by",
"      <strong>",
"       slow",
"      </strong>",
"      <strong>",
"       IV",
"      </strong>",
"      <strong>",
"       infusion",
"      </strong>",
"      , supplemented with fresh frozen plasma, prothrombin complex concentrate, or recombinant factor VIIa (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Vitamin K administration can be repeated every 12 hours for persistently elevated INR. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Significant or life-threatening bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our recommendations are consistent with the 2008 American College of Chest Physicians clinical practice guidelines (",
"      <a class=\"graphic graphic_table graphicRef61288 \" href=\"mobipreview.htm?15/63/16380\">",
"       table 1",
"      </a>",
"      ) and differ somewhat from the 2012 guidelines. (See",
"      <a class=\"local\" href=\"#H9418662\">",
"       'ACCP guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracranial imaging should be performed in all patients with head trauma who are receiving anticoagulation. Management of",
"      <strong>",
"       intracerebral hemorrhage",
"      </strong>",
"      in a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -treated patient is discussed separately. (See",
"      <a class=\"local\" href=\"#H21790994\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/1\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/2\">",
"      Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/3\">",
"      Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/4\">",
"      Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke 2011; 42:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/5\">",
"      Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/6\">",
"      Visser LE, Bleumink GS, Trienekens PH, et al. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 2004; 127:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/7\">",
"      Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/8\">",
"      Cavallaro R, Iovino P, Castiglione F, et al. Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. Eur J Gastroenterol Hepatol 2004; 16:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/9\">",
"      Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. BMJ 2010; 340:c1813. Also available at: BMJ 2010; 340:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/10\">",
"      Banet GA, Waterman AD, Milligan PE, et al. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003; 123:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/11\">",
"      Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006; 47:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/12\">",
"      Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/13\">",
"      Veeger NJ, Piersma-Wichers M, Meijer K, Hillege HL. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. Br J Haematol 2011; 153:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/14\">",
"      Kucher N, Connolly S, Beckman JA, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/15\">",
"      Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/16\">",
"      Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/17\">",
"      Bauman ME, Black K, Bauman ML, et al. Warfarin induced coagulopathy in children: assessment of a conservative approach. Arch Dis Child 2011; 96:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/18\">",
"      Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/19\">",
"      Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997; 126:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/20\">",
"      Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/21\">",
"      Wilson SE, Watson HG, Crowther MA. Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 2004; 170:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/22\">",
"      Dezee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/23\">",
"      Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/24\">",
"      Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost 2002; 88:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/25\">",
"      Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis 2001; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/26\">",
"      Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR&gt;10. Thromb Res 2004; 113:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/27\">",
"      Baker P, Gleghorn A, Tripp T, et al. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 2006; 133:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/28\">",
"      Chirputkar SK, Poole HJ, McNeil RC, et al. Reversal of asymptomatic over-anticoagulation with oral vitamin K. Br J Haematol 2006; 135:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/29\">",
"      Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/30\">",
"      O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/31\">",
"      Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/32\">",
"      Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/33\">",
"      Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/34\">",
"      Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/35\">",
"      Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/36\">",
"      Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/37\">",
"      Evans SJ, Biss TT, Wells RH, Hanley JP. Emergency warfarin reversal with prothrombin complex concentrates: UK wide study. Br J Haematol 2008; 141:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/38\">",
"      Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/39\">",
"      Laposata M, Van Cott EM, Lev MH. Case records of the Massachusetts General Hospital. Case 1-2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status. N Engl J Med 2007; 356:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/40\">",
"      Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000; 36:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/41\">",
"      Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/42\">",
"      Waien SA, Hayes D Jr, Leonardo JM. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N Engl J Med 2001; 345:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/43\">",
"      Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007; 82:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/44\">",
"      Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 1993; 153:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/45\">",
"      Nakagawa K, Hirota Y, Sawada N, et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 2010; 468:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/46\">",
"      Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/47\">",
"      Masters SJ, McClean PM, Arcarese JS, et al. Skull x-ray examinations after head trauma. Recommendations by a multidisciplinary panel and validation study. N Engl J Med 1987; 316:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/48\">",
"      Volans AP. The risks of minor head injury in the warfarinised patient. J Accid Emerg Med 1998; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/49\">",
"      Garra G, Nashed AH, Capobianco L. Minor head trauma in anticoagulated patients. Acad Emerg Med 1999; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/50\">",
"      Li J, Brown J, Levine M. Mild head injury, anticoagulants, and risk of intracranial injury. Lancet 2001; 357:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/51\">",
"      Brewer ES, Reznikov B, Liberman RF, et al. Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication. J Trauma 2011; 70:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/52\">",
"      Peck KA, Sise CB, Shackford SR, et al. Delayed intracranial hemorrhage after blunt trauma: are patients on preinjury anticoagulants and prescription antiplatelet agents at risk? J Trauma 2011; 71:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/53\">",
"      Shields RC, McBane RD, Kuiper JD, et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 2001; 76:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/54\">",
"      Burbury KL, Milner A, Snooks B, et al. Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: safe, reliable and convenient*. Br J Haematol 2011; 154:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/8/30857/abstract/55\">",
"      Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1324 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-6660D27D4F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30857=[""].join("\n");
var outline_f30_8_30857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Medical causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vitamin K deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Falsely elevated INRs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INR &lt;5 without bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INR 5 to 9 without bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Stopping warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stopping warfarin plus oral vitamin K",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Route of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acenocoumarol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INR &gt;9 without bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elevated INR with minimal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Significant or life-threatening bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Superwarfarin poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21790898\">",
"      Vitamin K formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HEAD TRAUMA AND INTRACRANIAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21790994\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21791001\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGERY/INVASIVE PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9418662\">",
"      ACCP GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/63/16380\" title=\"table 1\">",
"      Supratherapeutic INR management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 2\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=related_link\">",
"      Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30858="Cyclosporine (systemic): Drug information";
var content_f30_8_30858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclosporine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=see_link\">",
"    see \"Cyclosporine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=see_link\">",
"    see \"Cyclosporine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8012536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gengraf&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      SandIMMUNE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cyclosporine&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      Rhoxal-cyclosporine;",
"     </li>",
"     <li>",
"      Sandimmune&reg; I.V.;",
"     </li>",
"     <li>",
"      Sandoz-Cyclosporine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8015573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcineurin Inhibitor;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8012583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Neoral&reg;/Gengraf&reg; and Sandimmune&reg; are not bioequivalent and cannot be used interchangeably.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Newly-transplanted patients:",
"     </b>",
"     Adjunct therapy with corticosteroids is recommended. Initial dose should be given 4-12 hours prior to transplant or may be given postoperatively; adjust initial dose to achieve desired plasma concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Dose is dependent upon type of transplant and formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cyclosporine (modified):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Renal: 9 &plusmn; 3 mg/kg/day, divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Liver: 8 &plusmn; 4 mg/kg/day, divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Heart: 7 &plusmn; 3 mg/kg/day, divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cyclosporine (non-modified): Initial doses of 10-14 mg/kg/day have been used for renal transplants (the manufacturer&rsquo;s labeling includes dosing from initial clinical trials of 15 mg/kg/day [range: 14-18 mg/kg/day]; however, this higher dosing level is rarely used any longer). Continue initial dose daily for 1-2 weeks; taper by 5% per week to a maintenance dose of 5-10 mg/kg/day; some renal transplant patients may be dosed as low as 3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When using the non-modified formulation, cyclosporine levels may increase in liver transplant patients when the T-tube is closed; dose may need decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Cyclosporine (non-modified): Manufacturer's labeling: Initial dose: 5-6 mg/kg/day or one-third of the oral dose as a single dose, infused over 2-6 hours; use should be limited to patients unable to take capsules or oral solution; patients should be switched to an oral dosage form as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Many transplant centers administer cyclosporine as \"divided dose\" infusions (in 2-3 doses/day) or as a continuous (24-hour) infusion; dosages range from 3-7.5 mg/kg/day. Specific institutional protocols should be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: Conversion to cyclosporine (modified) from cyclosporine (non-modified):",
"     </b>",
"     Start with daily dose previously used and adjust to obtain preconversion cyclosporine trough concentration. Plasma concentrations should be monitored every 4-7 days and dose adjusted as necessary, until desired trough level is obtained. When transferring patients with previously poor absorption of cyclosporine (non-modified), monitor trough levels at least twice weekly (especially if initial dose exceeds 10 mg/kg/day); high plasma levels are likely to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Cyclosporine (modified): Initial dose: 2.5 mg/kg/day, divided twice daily; salicylates, NSAIDs, and oral glucocorticoids may be continued (refer to Drug Interactions); dose may be increased by 0.5-0.75 mg/kg/day if insufficient response is seen after 8 weeks of treatment; additional dosage increases may be made again at 12 weeks (maximum dose: 4 mg/kg/day). Discontinue if no benefit is seen by 16 weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Oral: Cyclosporine (modified): Initial dose: 2.5 mg/kg/day, divided twice daily; dose may be increased by 0.5 mg/kg/day if insufficient response is seen after 4 weeks of treatment; additional dosage increases may be made every 2 weeks if needed (maximum dose: 4 mg/kg/day). Discontinue if no benefit is seen by 6 weeks of therapy. Once patients are adequately controlled, the dose should be decreased to the lowest effective dose. Doses &lt;2.5 mg/kg/day may be effective. Treatment longer than 1 year is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Focal segmental glomerulosclerosis (unlabeled use):",
"     </b>",
"     Oral: Initial: 3.5-5 mg/kg/day divided every 12 hours (in combination with oral prednisone) (Braun, 2008; Cattran, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis (unlabeled use):",
"     </b>",
"     Oral: Initial: 4 mg/kg/day for 1 month (reduce dose if trough concentrations &gt;200 ng/mL); reduce dose by 0.5 mg/kg every 2 weeks to a maintenance dose of 2.5-3 mg/kg/day (Moroni, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Severe ulcerative colitis (steroid-refractory) (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: Cyclosporine (non-modified): 2-4 mg/kg/day, infused continuously over 24 hours. (Lichtiger, 1994; Van Assche, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     Some studies suggest no therapeutic difference between low-dose (2 mg/kg) and high-dose (4 mg/kg) cyclosporine regimens (Van Assche, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: Cyclosporine (modified): 2.3-3 mg/kg every 12 hours (De Saussure, 2005; Weber, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients responsive to I.V. therapy should be switched to oral therapy when possible.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8012582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=see_link\">",
"      see \"Cyclosporine (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Transplant:",
"     </b>",
"     Refer to adult dosing. Children may require, and are able to tolerate, larger doses than adults.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8012644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"     <b>",
"      Sandimmune&reg; and Neoral&reg;/Gengraf&reg; are not bioequivalent and cannot be used interchangeably.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8012645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For severe psoriasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Serum creatinine levels &ge;25% above pretreatment levels:",
"     </b>",
"     Take another sample within 2 weeks; if the level remains &ge;25% above pretreatment levels, decrease dosage of cyclosporine (modified) by 25% to 50%. If two dosage adjustments do not reverse the increase in serum creatinine levels, treatment should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Serum creatinine levels &ge;50% above pretreatment levels:",
"     </b>",
"     Decrease cyclosporine dosage by 25% to 50%. If two dosage adjustments do not reverse the increase in serum creatinine levels, treatment should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8012646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustment is probably necessary; monitor levels closely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gengraf&reg;: 25 mg, 100 mg [contains ethanol 12.8%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [non-modified]: 25 mg [DSC], 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral [modified]: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neoral&reg;: 25 mg, 100 mg [contains corn oil, dehydrated ethanol 11.9%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral [non-modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 25 mg, 100 mg [contains corn oil, dehydrated ethanol 12.7%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [non-modified]: 50 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 50 mg/mL (5 mL) [contains ethanol 32.9%, polyoxyethylated castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [modified]: 100 mg/mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gengraf&reg;: 100 mg/mL (50 mL) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neoral&reg;: 100 mg/mL (50 mL) [contains corn oil, dehydrated ethanol 11.9%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [non-modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 100 mg/mL (50 mL) [contains ethanol 12.5%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes non-modified solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8012649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Do not administer liquid from plastic or styrofoam cup. May dilute Neoral&reg; oral solution with orange juice or apple juice. May dilute Sandimmune&reg; oral solution with milk, chocolate milk, or orange juice. Avoid changing diluents frequently. Mix thoroughly and drink at once. Use syringe provided to measure dose. Mix in a glass container and rinse container with more diluent to ensure total dose is taken. Do not rinse syringe before or after use (may cause dose variation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combination therapy with renal transplantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Everolimus: Administer cyclosporine at the same time as everolimus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sirolimus: Administer cyclosporine 4 hours prior to sirolimus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: The manufacturer recommends that following dilution, intravenous admixture be administered over 2-6 hours. However, many transplant centers administer as divided doses (2-3 doses/day) or as a 24-hour continuous infusion. Discard solution after 24 hours. Anaphylaxis has been reported with I.V. use; reserve for patients who cannot take oral form. Patients should be under continuous observation for at least the first 30 minutes of the infusion, and should be monitored frequently thereafter. Maintain patent airway; other supportive measures and agents for treating anaphylaxis should be present when I.V. drug is given. To minimize leaching of DEHP, non-PVC sets should be used for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent - use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8012567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, fat emulsion 10%, fat emulsion 20%, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ampicillin,  anidulafungin, caspofungin, cefazolin, cefotaxime, cefoxitin, cefuroxime, chloramphenicol, ciprofloxacin, clindamycin, doripenem, doxyclycine, erythromycin lactobionate, gentamicin, kanamycin, linezolid, meropenem, metronidazole, micafungin, minocycline, nafcillin, oxacillin, penicillin G potassium, piperacillin, propofol, sargramostim, sulfamethoxazole/trimethoprim, ticarcillin/clavulanic acid, tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B cholesteryl sulfate complex, drotrecogin alfa, mycophenolate, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, magnesium sulfate, ondansetron, telavancin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8012553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of organ rejection in kidney, liver, and heart transplants, has been used with azathioprine and/or corticosteroids; severe, active rheumatoid arthritis (RA) not responsive to methotrexate alone; severe, recalcitrant plaque psoriasis in nonimmunocompromised adults unresponsive to or unable to tolerate other systemic therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8012555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allogenic stem cell transplants for prevention and treatment of graft-versus-host disease; also used in some cases of severe autoimmune disease (eg, SLE) that are resistant to corticosteroids and other therapy; focal segmental glomerulosclerosis; severe ulcerative colitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8012538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CycloSPORINE may be confused with cyclophosphamide, Cyklokapron&reg;, cycloSERINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CycloSPORINE modified (Neoral&reg;, Gengraf&reg;) may be confused with cycloSPORINE non-modified (SandIMMUNE&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gengraf&reg; may be confused with Prograf&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neoral&reg; may be confused with Neurontin&reg;, Nizoral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SandIMMUNE&reg; may be confused with SandoSTATIN&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8012603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with systemic use, including rheumatoid arthritis, psoriasis, and transplantation (kidney, liver, and heart). Percentages noted include the highest frequency regardless of indication/dosage. Frequencies may vary for specific conditions or formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (8% to 53%), edema (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hirsutism (21% to 45%), hypertrichosis (5% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (15%), female reproductive disorder (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (23%), diarrhea (3% to 13%), gum hyperplasia (2% to 16%), abdominal discomfort (&lt;1% to 15%), dyspepsia (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (7% to 55%), paresthesia (1% to 11%), leg cramps/muscle contractions (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal dysfunction/nephropathy (10% to 38%), creatinine increased (16% to &ge;50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (1% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (3% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (4% to 6%), arrhythmia (2% to 5%), flushes (&lt;1% to 5%), abnormal heart sounds, cardiac failure, glomerular capillary thrombosis, MI, peripheral ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), pain (6%), convulsions (1% to 5%), insomnia (4%), psychiatric events (4% to 5%), pain (3% to 4%), depression (1% to 6%), migraine (2% to 3%), anxiety, confusion, fever, hypoesthesia, emotional lability, impaired concentration, lethargy, malaise, nervousness, paranoia, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Purpura (3% to 4%), acne (1% to 6%), brittle fingernails, hair breaking, abnormal pigmentation, angioedema, cellulitis, dermatitis, dry skin, eczema, folliculitis, keratosis, pruritus, rash, skin disorder, skin malignancies, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (&lt;1% to 4%), menstrual disorder (1% to 3%), breast fibroadenosis, breast pain, hyper-/hypoglycemia, diabetes mellitus, goiter, hot flashes, hyperkalemia, hyperuricemia, hypomagnesemia, libido increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (2% to 10%), flatulence (5%), gingivitis (up to 4%), cramps (up to 4%), anorexia, constipation, dry mouth, dysphagia, enanthema, eructation, esophagitis, gastric ulcer, gastritis, gastroenteritis, gastrointestinal bleeding (upper), gingival bleeding, glossitis, mouth sores, peptic ulcer, pancreatitis, swallowing difficulty, salivary gland enlargement, taste perversion, tongue disorder, gum hyperplasia, weight loss/gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Leukorrhea (1%), abnormal urine, micturition increased, micturition urgency, nocturia, polyuria, pyelonephritis, urinary incontinence, uterine hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (&lt;1% to 6%), anemia, bleeding disorder, clotting disorder, platelet disorder, red blood cell disorder, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (&lt;1% to 7%), hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1% to 6%), bone fracture, joint dislocation, joint pain, muscle pain, myalgia, neuropathy, stiffness, synovial cyst, tendon disorder, tingling, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis, eye pain, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness, hearing loss, tinnitus, vestibular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, hematuria, renal abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (&lt;1% to 7%), bronchospasm (up to 5%), cough (3% to 5%), pharyngitis (3% to 5%), dyspnea (1% to 5%), rhinitis (up to 5%), abnormal chest sounds, epistaxis, respiratory infection, pneumonia (up to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (8% to 10%), lymphoma (&lt;1% to 6% reported in transplant), abscess, allergic reactions, bacterial infection, carcinoma, diaphoresis increased, fungal infection, herpes simplex, herpes zoster, hiccups, lymphadenopathy, moniliasis, night sweats, tonsillitis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Postmarketing and/or case reports (any indication):",
"     </b>",
"     Anaphylaxis/anaphylactoid reaction (possibly associated with Cremophor&reg; EL vehicle in injection formulation), benign intracranial hypertension, cholesterol increased, death (due to renal deterioration), encephalopathy, gout, hyperbilirubinemia, hyperkalemia, impaired consciousness, infections (increased risk; including JC virus and BK virus), migraine headache, neurotoxicity, papilloedema, polyoma virus-associated nephropathy (PVAN), progressive multifocal leukoencephalopathy (PML), pulmonary edema (noncardiogenic), reversible posterior leukoencephalopathy syndrome (RPLS), thrombotic microangiopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8012561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclosporine or any component of the formulation. I.V. cyclosporine is contraindicated in hypersensitivity to polyoxyethylated castor oil (Cremophor&reg; EL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rheumatoid arthritis and psoriasis: Abnormal renal function, uncontrolled hypertension, malignancies. Concomitant treatment with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, coal tar, or radiation therapy are also contraindications for use in patients with psoriasis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8012600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Liver injury, including cholestasis, jaundice, hepatitis, and liver failure, has been reported. These events were mainly in patients with confounding factors including infections, coadministration with other potentially hepatotoxic medications, underlying conditions, and significant comorbidities. Fatalities have also been reported rarely, primarily in transplant patients. Increased hepatic enzymes and bilirubin have occurred (when used at high doses); improvement usually seen with dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Significant hyperkalemia, with or without hyperchloremic metabolic acidosis, has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension:",
"     <b>",
"      [U.S. Boxed Warning]: May cause hypertension.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperuricemia: Significant hyperuricemia has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Increased risk of infection with use; fatal infections have been reported.",
"     </b>",
"     Bacterial, viral, fungal, and protozoal infections (including opportunistic infections) have occurred. Polyoma virus infections, such as the JC virus and BK virus, may result in serious and sometimes fatal outcomes. The JC virus is associated with progressive multifocal leukoencephalopathy (PML), and PML has been reported in patients receiving cyclosporine. PML may be fatal and presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia; consider neurologic consultation as indicated. The BK virus is associated with nephropathy, and polyoma virus-associated nephropathy (PVAN) has been reported in patients receiving cyclosporine. PVAN is associated with serious adverse effects including renal dysfunction and renal graft loss. If PML or PVAN occur in transplant patients, consider reducing immunosuppression therapy as well as the risk  that reduced immunosuppression poses to grafts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Increased risk of lymphomas and other malignancies (including fatal outcomes) with use, particularly those of the skin;",
"     </b>",
"     risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Renal impairment, including structural kidney damage has occurred (when used at high doses); monitor renal function closely.",
"     </b>",
"     Use caution with other potentially nephrotoxic drugs (eg, acyclovir, aminoglycoside antibiotics, amphotericin B, ciprofloxacin). Elevations in serum creatinine and BUN associated with nephrotoxicity generally respond to dosage reductions.  In renal transplant patients with rapidly rising BUN and creatinine, carefully evaluate to differentiate between cyclosporine-associated nephrotoxicity and renal rejection episodes. In cases of severe rejection that fail to respond to pulse steroids and monoclonal antibodies, switching to an alternative immunosuppressant agent may be preferred  to increasing cyclosporine to an excessive dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: May cause seizures, particularly if used with high-dose corticosteroids. Encephalopathy has also been reported; predisposing factors include hypertension, hypomagnesemia, hypocholesterolemia, high-dose corticosteroids, high cyclosporine serum concentration, and graft-versus-host disease (GVHD). Encephalopathy may be more common in patients with liver transplant compared to kidney transplant. Other neurotoxic events, such as optic disc edema (including papilloedema and potential visual impairment), have been rarely reported primarily in transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Risk of skin cancer may be increased in psoriasis patients with a history of PUVA and possibly methotrexate or other immunosuppressants, UVB, coal tar, or radiation;",
"     </b>",
"     increased risk of skin cancer has also been established in transplant patients; risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic microangiopathy: In transplant patients, syndromes of microangiopathic hemolytic anemia and thrombocytopenia have occurred and may result in graft failure; it is accompanied by platelet consumption within the graft. Syndrome may occur without graft rejection. Although management of the syndrome is unclear, discontinuation or reduction of cyclosporine, in addition to streptokinase and heparin administration or plasmapheresis, has been associated with syndrome resolution. However, resolution seems to be dependent upon early detection of the syndrome via indium 111 labeled platelet scans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Appropriate use: If receiving other immunosuppressive agents, radiation or UV therapy, concurrent use of cyclosporine is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyclosporine combination therapy in renal transplant: Due to the increased risk for nephrotoxicity in renal transplantation, avoid using standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended; monitor cyclosporine concentrations closely. Cyclosporine and everolimus combination therapy may increase the risk for proteinuria. Cyclosporine combined with either everolimus or sirolimus may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy for use in psoriasis have not been established in children. Safety and efficacy for use in juvenile idiopathic arthritis (JIA) have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transplant patients: To be used initially with corticosteroids. Make dose adjustments based on cyclosporine blood concentrations. Anaphylaxis has been reported with I.V. use; reserve for patients who cannot take oral form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corn oil: Product may contain corn oil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol: Products may contain ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Non-interchangeability of modified/non-modified forms: Use caution when changing dosage forms; products are not equally interchangeable. Cyclosporine (modified) refers to the capsule dosage formulation of cyclosporine in an aqueous dispersion (previously referred to as &ldquo;microemulsion&rdquo;).",
"     <b>",
"      [U.S. Boxed Warning]: Cyclosporine (modified) has increased bioavailability as compared to cyclosporine (non-modified) and cannot be used interchangeably without close monitoring.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyoxyethylated castor oil: Cyclosporine for injection contains polyoxyethylated castor oil (Cremaphor&reg; EL), which is associated with hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol: Products may contain propylene glycol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Adjustment of dose should only be made under the direct supervision of an experienced physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring of concentrations: Monitor cyclosporine concentrations closely following the addition, modification, or deletion of other medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Live, attenuated vaccines may be less effective; use should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8012607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AcetaZOLAMIDE: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: CycloSPORINE (Systemic) may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambrisentan: CycloSPORINE (Systemic) may increase the serum concentration of Ambrisentan.  Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androgens: May enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: CycloSPORINE (Systemic) may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir. Management: Cyclosporine dose adjustments will likely be necessary when used together with boceprevir.  Monitor serum cyclosporine concentrations closely, and monitor patients for evidence of cyclosporine toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: CycloSPORINE (Systemic) may decrease the metabolism of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin.  Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer cyclosporine at least 4 hours prior to colesevelam.  Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: CycloSPORINE (Systemic) may increase the serum concentration of DOXOrubicin.  Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CycloSPORINE (Systemic) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: CycloSPORINE (Systemic) may decrease the metabolism of Etoposide.  Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: CycloSPORINE (Systemic) may increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CycloSPORINE (Systemic) may increase the serum concentration of Everolimus.  Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: CycloSPORINE (Systemic) may diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of CycloSPORINE (Systemic). Management: Monitor for altered cyclosporine concentrations/effects if grapefruit intake is increased/decreased.  Advise patients to not alter their pattern of grapefruit/grapefruit juice intake without consulting their healthcare provider.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: CycloSPORINE (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may increase the serum concentration of CycloSPORINE (Systemic). Imipenem may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CycloSPORINE (Systemic) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melphalan: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: CycloSPORINE (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CycloSPORINE (Systemic) may increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May increase the absorption of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minoxidil (Systemic): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minoxidil (Topical): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: CycloSPORINE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norfloxacin: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer orlistat at least 3 hours before or after oral cyclosporine.  Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic).  Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): CycloSPORINE (Systemic) may increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinupristin: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: CycloSPORINE (Systemic) may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Rosuvastatin.  Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED]. Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitaxentan: CycloSPORINE (Systemic) may increase the serum concentration of Sitaxentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Consider alternatives to St. John's wort (SJW). If the combination cannot be avoided, monitor for decreased cyclosporine concentrations/effects.  Monitor for increased cyclosporine concentrations/effects following SJW discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Significant cyclosporine dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both cyclosporine concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8012612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice increases cyclosporine serum concentrations. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may increase the metabolism of and decrease plasma levels of cyclosporine; organ rejection and graft loss have been reported. Cat's claw and echinacea have immunostimulant properties. Management: Avoid St John's wort, cat's claw, and echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8012556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8012557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies (using doses that were not maternally toxic). In humans, cyclosporine crosses the placenta; maternal concentrations do not correlate with those found in the umbilical cord. Cyclosporine may be detected in the serum of newborns for several days after birth. Based on clinical use, premature births and low birth weight were consistently observed in pregnant transplant patients (additional pregnancy complications also present).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     A pregnancy registry has been established for pregnant women taking immunosuppressants following any solid organ transplant (National Transplantation Pregnancy Registry, Temple University, 877-955-6877).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     A pregnancy registry has also been established for pregnant women taking Neoral&reg; for psoriasis or rheumatoid arthritis (Neoral&reg; Pregnancy Registry for Psoriasis and Rheumatoid Arthritis, Thomas Jefferson University, 888-522-5581).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8012559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16336615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyclosporine is excreted in breast milk. Breast feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8012648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer this medication consistently with relation to time of day and meals. Avoid grapefruit juice with oral cyclosporine use.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8012694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CycloSPORINE Modified Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $41.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $82.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $164.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CycloSPORINE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $58.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $232.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Gengraf Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $47.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $191.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Neoral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $1.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $6.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (SandIMMUNE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $2.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $11.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CycloSPORINE Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (5 mL): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CycloSPORINE Modified Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (50 mL): $299.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gengraf Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (50 mL): $360.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neoral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (50 mL): $367.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SandIMMUNE Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (5 mL): $45.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SandIMMUNE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (50 mL): $561.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8012654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and serum creatinine after any cyclosporine dosage changes or addition, modification, or deletion of other medications. Monitor plasma concentrations periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Transplant patients: Cyclosporine trough levels, serum electrolytes, renal function, hepatic function, blood pressure, lipid profile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psoriasis therapy: Baseline blood pressure, serum creatinine (2 levels each), BUN, CBC, serum magnesium, potassium, uric acid, lipid profile. Biweekly monitoring of blood pressure, complete blood count, and levels of BUN, uric acid, potassium, lipids, and magnesium during the first 3 months of treatment for psoriasis. Monthly monitoring is recommended after this initial period. Also evaluate any atypical skin lesions prior to therapy. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis: Baseline blood pressure, and serum creatinine (2 levels each); serum creatinine every 2 weeks for first 3 months, then monthly if patient is stable. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8012570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reference ranges are method dependent and specimen dependent; use the same analytical method consistently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Method-dependent and specimen-dependent:",
"     </b>",
"     Trough levels should be obtained:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 12-18 hours after dose (chronic usage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 12 hours after dose",
"     <b>",
"      or",
"     </b>",
"     immediately prior to next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapeutic range: Not absolutely defined, dependent on organ transplanted, time after transplant, organ function and CsA toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     General range of 100-400 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic level: Not well defined, nephrotoxicity may occur at any level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Recommended cyclosporine therapeutic ranges when administered in combination with everolimus for renal transplant",
"     </i>",
"     (Zortress&reg; product labeling, 2013):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Month 1 post-transplant: 100-200 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 2 and 3 post-transplant: 75-150 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 4 and 5 post-transplant: 50-100 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 6-12 post-transplant: 25-50 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arpimune (PH);",
"     </li>",
"     <li>",
"      Biosporin (EC);",
"     </li>",
"     <li>",
"      Capimune (GB);",
"     </li>",
"     <li>",
"      Cermox (AR);",
"     </li>",
"     <li>",
"      Ciclohexal (ZA);",
"     </li>",
"     <li>",
"      Cicloral (AU, DE);",
"     </li>",
"     <li>",
"      Cipol-N (KP);",
"     </li>",
"     <li>",
"      Consupren (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cyrin (PH);",
"     </li>",
"     <li>",
"      Deximune (GB, IL);",
"     </li>",
"     <li>",
"      Equoral (EE, TH);",
"     </li>",
"     <li>",
"      Gengraf (BR, HK, MY);",
"     </li>",
"     <li>",
"      Implanta (KP);",
"     </li>",
"     <li>",
"      Imusporin (CO, IN);",
"     </li>",
"     <li>",
"      Kasporin (TH);",
"     </li>",
"     <li>",
"      Neoral (FR, GB, IE, NZ, TW);",
"     </li>",
"     <li>",
"      Osporin (PH);",
"     </li>",
"     <li>",
"      Sanda (TH);",
"     </li>",
"     <li>",
"      Sandimmun (AT, AU, BE, BF, BJ, CH, CI, CN, CZ, DE, DK, EE, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IT, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NO, NZ, PE, PH, PK, PL, PT, RU, SC, SD, SE, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Sandimmun Neoral (AE, AR, AT, AU, BH, BR, CH, CN, CY, CZ, EE, EG, FI, GB, GR, HK, ID, IL, IQ, IR, JO, KP, KW, LB, LY, MY, NO, OM, PE, PH, PL, PY, QA, SA, SE, SY, TH, TR, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Sandimmune (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8012568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8012571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (non-modified): Erratic and incomplete; dependent on presence of food, bile acids, and GI motility; larger oral doses are needed in pediatrics due to shorter bowel length and limited intestinal absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (modified): Erratic and incomplete; increased absorption, up to 30% when compared to cyclosporine (non-modified); less dependent on food, bile acids, or GI motility when compared to cyclosporine (non-modified)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely in tissues and body fluids including the liver, pancreas, and lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4-6 L/kg in renal, liver, and marrow transplant recipients (slightly lower values in cardiac transplant patients; children &lt;10 years have higher values)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 98% to lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4; forms at least 25 metabolites; extensive first-pass effect following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (non-modified): Dependent on patient population and transplant type (&lt;10% in adult liver transplant patients and as high as 89% in renal transplant patients); bioavailability of Sandimmune&reg; capsules and oral solution are equivalent; bioavailability of oral solution is ~30% of the I.V. solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 28% (range: 17% to 42%); gut dysfunction common in BMT patients and oral bioavailability is further reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (modified): Bioavailability of Neoral&reg; capsules and oral solution are equivalent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 43% (range: 30% to 68%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 23% greater than with cyclosporine (non-modified) in renal transplant patients; 50% greater in liver transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: May be prolonged in patients with hepatic impairment and shorter in pediatric patients due to the higher metabolism rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (non-modified): Biphasic: Alpha: 1.4 hours; Terminal: 19 hours (range: 10-27 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (modified): Biphasic: Terminal: 8.4 hours (range: 5-18 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (non-modified): 2-6 hours; some patients have a second peak at 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine (modified): Renal transplant: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (6%, 0.1% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andrews DJ and Cramb R, &ldquo;Cyclosporin: Revisions in Monitoring Guidelines and Review of Current Analytical Methods,&rdquo;",
"      <i>",
"       Ann Clin Biochem",
"      </i>",
"      , 2002, 39(Pt 5):424-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/12227848/pubmed\" id=\"12227848\" target=\"_blank\">",
"        12227848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benfield MR, Tejani A, Harmon WE, et al, &ldquo;A Randomized Multicenter Trial of OKT3 mAbs Induction Compared With Intravenous Cyclosporine in Pediatric Renal Transplantation,&rdquo;",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2005, 9(3):282-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/15910382/pubmed\" id=\"15910382\" target=\"_blank\">",
"        15910382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boni R and Dummer R, &ldquo;Abscessed Inflammation as a Serious Complication of Low Dose Cyclosporin A in Atopic Dermatitis,&rdquo;",
"      <i>",
"       Eur J Dermatol",
"      </i>",
"      , 1995, 5:268-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braun N, Schmutzler F, Lange C, et al, &ldquo;Immunosuppressive Treatment for Focal Segmental Glomerulosclerosis in Adults,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2008, (3):CD003233.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/18646090/pubmed\" id=\"18646090\" target=\"_blank\">",
"        18646090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Caforio AL, Gambino A, Tona F, &ldquo;Sulfinpyrazone Reduces Cyclosporine Levels: A New Drug Interaction in Heart Transplant Recipients,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2000, 19(12):1205-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/11124491/pubmed\" id=\"11124491\" target=\"_blank\">",
"        11124491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cattran DC, Appel GB, Hebert LA, et al, &ldquo;A Randomized Trial of Cyclosporine in Patients With Steroid-Resistant Focal Segmental Glomerulosclerosis. North America Nephrotic Syndrome Study Group,&rdquo;",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 1999, 56(6):2220-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/10594798/pubmed\" id=\"10594798\" target=\"_blank\">",
"        10594798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Claris O, Picaud JC, Brazier JL, et al, \"Pharmacokinetics of Cyclosporin A in 16 Newborn Infants of Renal or Cardiac Transplant Mothers,\"",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1993, 20(3-4):180-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7828451/pubmed\" id=\"7828451\" target=\"_blank\">",
"        7828451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies MG and Bowers PW, &ldquo;Alopecia Areata Arising in Patients Receiving Cyclosporin Immunosuppression,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1995, 132(5):835-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7772501/pubmed\" id=\"7772501\" target=\"_blank\">",
"        7772501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Saussure P, Soravia C, Morel P, et al, &ldquo;Low-Dose Oral Microemulsion Ciclosporin for Severe, Refractory Ulcerative Colitis,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2005, 22(3):203-08.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/16091057/pubmed\" id=\"16091057\" target=\"_blank\">",
"        16091057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ducharme MP, Warbasse LH, and Edwards DJ, &ldquo;Disposition of Intravenous and Oral Cyclosporine After Administration With Grapefruit Juice,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(5):485-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7768070/pubmed\" id=\"7768070\" target=\"_blank\">",
"        7768070",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunn CJ, Wagstaff AJ, Perry CM, et al, \"Cyclosporin: An Updated Review of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral)1 in Organ Transplantation,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2001, 61(13):1957-2016.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/11708766/pubmed\" id=\"11708766\" target=\"_blank\">",
"        11708766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higgins EM, Hughes JR, Snowden S, et al, &ldquo;Cyclosporin-Induced Periungual Granulation Tissue,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1995, 132(5):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7772496/pubmed\" id=\"7772496\" target=\"_blank\">",
"        7772496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander AA, van Rooij J, Lentjes GW, et al, &ldquo;The Effect of Grapefruit Juice on Cyclosporine and Prednisone Metabolism in Transplant Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):318-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7697949/pubmed\" id=\"7697949\" target=\"_blank\">",
"        7697949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt DW, Mueller EA, Kovarik JM, et al, &ldquo;Sandimmune&reg; Neoral&reg; Pharmacokinetics: Impact of the New Oral Formulation,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1995, 27(1):1434-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7878935/pubmed\" id=\"7878935\" target=\"_blank\">",
"        7878935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Honcharik N and Anthone S, &ldquo;Activated Charcoal in Acute Cyclosporine Overdose,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985, 1(8436):1051.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horton RC and Bonser RS, &ldquo;Interaction Between Cyclosporin and Fluoxetine,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 311(7002):422.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7640589/pubmed\" id=\"7640589\" target=\"_blank\">",
"        7640589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RL, &ldquo;Cyclosporine-Related Central Nervous System Toxicity in Cardiac Transplantation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(6):420-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/2370897/pubmed\" id=\"2370897\" target=\"_blank\">",
"        2370897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kabeer MH, Filo RS, Milgrom ML, et al, &ldquo;Central Pontine Myelinolysis Following Orthotopic Liver Transplant: Association With Cyclosporine Toxicity,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1995, 71(834):239-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7784287/pubmed\" id=\"7784287\" target=\"_blank\">",
"        7784287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman DB, Kaplan B, Kanwar YS, et al, &ldquo;The Successful Use of Tacrolimus (FK506) in a Pancreas/Kidney Transplant Recipient With Recurrent Cyclosporine-Associated Hemolytic Uremic Syndrome,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(12):1737-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7541579/pubmed\" id=\"7541579\" target=\"_blank\">",
"        7541579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kino KJ and Wittkowsky AK, &ldquo;Influence of Bile Acid Replacement on Cyclosporine Absorption in a Patient With Jejunoileal Bypass,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(3):350-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7667169/pubmed\" id=\"7667169\" target=\"_blank\">",
"        7667169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Abreu MT, Cohen R, et al, &ldquo;American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 30(3):940-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/16530532/pubmed\" id=\"16530532\" target=\"_blank\">",
"        16530532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin CY and Lee SF, &ldquo;Comparison of Pharmacokinetics Between CsA Capsules and Sandimmune&reg; Neoral&reg; in Pediatric Patients,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1994, 26(5):2973-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7940938/pubmed\" id=\"7940938\" target=\"_blank\">",
"        7940938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtiger S, Present DH, Kornbluth A, et al, &ldquo;Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(26):1841-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/8196726/pubmed\" id=\"8196726\" target=\"_blank\">",
"        8196726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntyre HD, Menzies B, Rigby R, et al, &ldquo;Long-Term Bone Loss After Renal Transplantation: Comparison of Immunosuppressive Regimens,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 1995, 9(1):20-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7742578/pubmed\" id=\"7742578\" target=\"_blank\">",
"        7742578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Memon M, de Magalhace-Silverman M, Bloom EJ, et al, &ldquo;Reversible Cyclosporine-Induced Cortical Blindness in Allogeneic Bone Marrow Transplant Recipients,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1995, 15(2):283-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7773219/pubmed\" id=\"7773219\" target=\"_blank\">",
"        7773219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moroni G, Doria A, Mosca M, et al, &ldquo;A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis Over Four Years,&rdquo;",
"      <i>",
"       Clin J Am Soc Nephrol",
"      </i>",
"      , 2006, 1(5):925-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/17699309/pubmed\" id=\"17699309\" target=\"_blank\">",
"        17699309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niese D, &ldquo;A Double-Blind Randomized Study of Sandimmune&reg; Neoral&reg; vs Sandimmune&reg; in New Renal Transplant Recipients: Results After 12 Months,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1995, 27(2):1849-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7725531/pubmed\" id=\"7725531\" target=\"_blank\">",
"        7725531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page RL 2nd, Ruscin JM, Fish D, et al, \"Possible Interaction Between Intravenous Azithromycin and Oral Cyclosporine,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(11):1436-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/11714218/pubmed\" id=\"11714218\" target=\"_blank\">",
"        11714218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Passfall J, Schuller I, and Keller F, &ldquo;Pharmacokinetics of Cyclosporin During Administration of Danazol,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 1994, 9(12):1807-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7708271/pubmed\" id=\"7708271\" target=\"_blank\">",
"        7708271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard S, Nashan B, Johnston A, et al, \"A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A. Berlin, Germany, November 19, 2001,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2003, 25(6): 1654-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/12860490/pubmed\" id=\"12860490\" target=\"_blank\">",
"        12860490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ratanatharathorn V, Nash RA, Przepiorka D, et al, \"Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 92(7):2303-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/9746768/pubmed\" id=\"9746768\" target=\"_blank\">",
"        9746768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scalzini A, Barni C, Stellini R, et al, &ldquo;Fatal Invasive Aspergillosis During Cyclosporine and Steroids Treatment for Crohn's Disease,&rdquo;",
"      <i>",
"       Dig Dis Sci",
"      </i>",
"      , 1995, 40(3):528.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7895537/pubmed\" id=\"7895537\" target=\"_blank\">",
"        7895537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma RK, Kumar P, Rai P, et al, &ldquo;Cyclosporine Neurotoxicity in a Renal-Transplant Recipient,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 1995, 70(2):269.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7566320/pubmed\" id=\"7566320\" target=\"_blank\">",
"        7566320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taesch S, Niese D, and Mueller EA, &ldquo;Sandimmune&reg; Neoral&reg;, A New Oral Formulation of Cyclosporine With Improved Pharmacokinetic Characteristics: Safety and Tolerability in Renal Transplant Patients,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1994, 26(6):3147-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7998097/pubmed\" id=\"7998097\" target=\"_blank\">",
"        7998097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tugwell P, Pincus T, Yocum D, et al, &ldquo;Combination Therapy With Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(3):137-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/7791814/pubmed\" id=\"7791814\" target=\"_blank\">",
"        7791814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Assche G, D&rsquo;Haens G, Noman M, et al, &ldquo;Randomized, Double-Blind Comparison of 4 mg/kg Versus 2 mg/kg Intravenous Cyclosporine in Severe Ulcerative Colitis,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2003, 125(4):1025-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/14517785/pubmed\" id=\"14517785\" target=\"_blank\">",
"        14517785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandstrat TL, Schroeder TJ, and Myre SA, &ldquo;Cyclosporine Pharmacokinetics in Pediatric Transplant Recipients,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1989, 11(5):493-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/2683250/pubmed\" id=\"2683250\" target=\"_blank\">",
"        2683250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber A, Fein F, Koch S, et al, &ldquo;Treatment of Ulcerative Colitis Refractory to Steroid Therapy by Oral Microemulsion Cyclosporin (Neoral),&rdquo;",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2006, 12(12):1131-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/17119387/pubmed\" id=\"17119387\" target=\"_blank\">",
"        17119387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells G and Tugwell P, &ldquo;Cyclosporin A in Rheumatoid Arthritis: Overview of Efficacy,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1993, 32(Suppl 1):51-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/8/30858/abstract-text/8448639/pubmed\" id=\"8448639\" target=\"_blank\">",
"        8448639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9094 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30858=[""].join("\n");
var outline_f30_8_30858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012536\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015573\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012583\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012582\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012644\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012645\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012646\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012692\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012552\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012649\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012567\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012553\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012555\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012538\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012603\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012561\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012600\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012607\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012608\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012612\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012556\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012557\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012559\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16336615\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012648\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012694\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012654\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012570\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961966\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012568\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012571\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/26/14756?source=related_link\">",
"      Cyclosporine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_8_30859="Risk factors for hearing loss";
var content_f30_8_30859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for sensorineural hearing loss in the newborn",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Genetic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prenatal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Postnatal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Perinatal infections (CMV, Syphilis, Toxoplasmosis, Rubella, HIV)",
"      </td>",
"      <td>",
"       Very low birth weight (&lt;1500g)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autosomal dominant",
"      </td>",
"      <td>",
"       Maternal diabetes",
"      </td>",
"      <td>",
"       Ischemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       X-linked",
"      </td>",
"      <td>",
"       Prenatal medication (antimalarials, aminoglycosides isoretinoin)",
"      </td>",
"      <td>",
"       Severe Hyperbilirubinemia (requiring exchange transfusion)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       Mitochondrial",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        Maternal drug abuse",
"       </p>",
"       <p>",
"        Lack of prenatal care",
"       </p>",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        Low APGAR score (&lt;4 at one min or &lt;6 at five min)",
"       </p>",
"       <p>",
"        Mechanical ventilation &gt; five days",
"       </p>",
"       <p>",
"        Meningitis (Bacterial , fungal)",
"       </p>",
"       <p>",
"        Ototoxic medications (aminoglycosides*, diuretics)",
"       </p>",
"       <p>",
"        ECMO",
"       </p>",
"       <p>",
"        PPHN",
"       </p>",
"       <p>",
"        Hypothyroidism",
"       </p>",
"       <p>",
"        ? Noise exposure",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    *Certain genetic predispositions appear to increase an infant's risk of aminoglycoside-related hearing loss",
"    <br>",
"     CMV: Cytomegalovirus infection; PPHN:Persistent pulmonary hypertension of the newborn; ECMO:Extracorporeal membrane oxygenation",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30859=[""].join("\n");
var outline_f30_8_30859=null;
var title_f30_8_30860="Physiologic Rx Malnutrition B";
var content_f30_8_30860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic basis for treatment of severe malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Affected organ or system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune system",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         All aspects of immunity are diminished",
"        </p>",
"        <p>",
"         Lymph glands, tonsils and the thymus are atrophied",
"        </p>",
"        <p>",
"         Cell-mediated (T-cell) immunity is severely depressed",
"        </p>",
"        <p>",
"         IgA levels in secretions are reduced",
"        </p>",
"        <p>",
"         Complement components are low",
"        </p>",
"        <p>",
"         Phagocytes do not kill ingested bacteria efficiently",
"        </p>",
"        <p>",
"         Tissue damage does not result in inflammation or migration of white cells to the affected area",
"        </p>",
"        <p>",
"         Acute phase immune response is diminished",
"        </p>",
"        <p>",
"         Typical signs of infection, such as an increased white cell count and fever, are frequently absent",
"        </p>",
"        <p>",
"         Hypoglycaemia and hypothermia are both signs of severe infection and are usually associated with septic shock",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Treat all children with broad-spectrum antimicrobials",
"        </p>",
"        <p>",
"         Because of the risk of transmission of infection, ensure that newly",
"admitted children are kept apart from children who are recovering from",
"infection",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrine system",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Insulin levels are reduced and the child has impaired glucose tolerance",
"        </p>",
"        <p>",
"         Insulin growth factor 1 (IGF-1) levels are reduced, although growth hormone levels are increased",
"        </p>",
"        <p>",
"         Cortisol levels are usually increased",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Give the child small, frequent feeds",
"        </p>",
"        <p>",
"         Do not give steroids",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Circulatory system",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Basic metabolic rate is reduced by about 30 percent",
"        </p>",
"        <p>",
"         Energy expenditure due to activity is very low",
"        </p>",
"       </td>",
"       <td>",
"        Keep the child warm to prevent",
"hypothermia; dry the child quickly and properly after washing and cover",
"with clothes and blankets, ensure that windows are kept closed at night",
"and keep the temperature of the living environment at 25-30 &ordm;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Both",
"heat generation and heat loss are impaired; the child becomes",
"hypothermic in a cold environment and hyperthermic in a hot environment",
"       </td>",
"       <td>",
"        If a child has fever, cool the child by sponging with tepid (not cold) water (never alcohol rubs)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30860=[""].join("\n");
var outline_f30_8_30860=null;
var title_f30_8_30861="Beta blockers drug interactions";
var content_f30_8_30861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major drug interactions with beta blockers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aluminum hydroxide gel",
"       </td>",
"       <td>",
"        Decreased beta-blocker adsorption and therapeutic effect",
"       </td>",
"       <td>",
"        Avoid&nbsp;beta-blocker-aluminum hydroxide combination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aminophylline",
"       </td>",
"       <td>",
"        Mutual inhibition",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        May induce cardiac arrest",
"       </td>",
"       <td>",
"        Combination should be used with extreme caution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidiabetic agents",
"       </td>",
"       <td>",
"        Enhanced hypoglycemia; hypertension",
"       </td>",
"       <td>",
"        Monitor for altered diabetic response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel inhibitors (verapamil, diltiazem)",
"       </td>",
"       <td>",
"        Potentiation of bradycardia, myocardial depression, and hypotension",
"       </td>",
"       <td>",
"        Avoid use, although few patients show ill effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"       <td>",
"        Prolongs half-life of propranolol",
"       </td>",
"       <td>",
"        Combination should be used with caution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"       <td>",
"        Hypertension during clonidine withdrawal",
"       </td>",
"       <td>",
"        Monitor for hypertensive response; withdraw&nbsp;beta-blocker before withdrawing clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitalis glycosides",
"       </td>",
"       <td>",
"        Potentiation of bradycardia",
"       </td>",
"       <td>",
"        Observe patient's response; interactions may benefit angina patients with abnormal ventricular function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine",
"       </td>",
"       <td>",
"        Hypertension; bradycardia",
"       </td>",
"       <td>",
"        Administer epinephrine cautiously; cardioselective&nbsp;beta-blocker may be safer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ergot alkaloids",
"       </td>",
"       <td>",
"        Excessive vasoconstriction",
"       </td>",
"       <td>",
"        Observe patient's response; few patients show ill effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucagon",
"       </td>",
"       <td>",
"        Inhibition of hyperglycemic effect",
"       </td>",
"       <td>",
"        Monitor for reduced response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Halofenate",
"       </td>",
"       <td>",
"        Reduced&nbsp;beta-blocking activity; induction of propranolol withdrawal rebound",
"       </td>",
"       <td>",
"        Observe for impaired response to&nbsp;beta-blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indomethacin",
"       </td>",
"       <td>",
"        Inhibition of antihypertensive response to&nbsp;beta-blockade",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoproterenol",
"       </td>",
"       <td>",
"        Mutual inhibition",
"       </td>",
"       <td>",
"        Avoid concurrent use or choose cardiac-selective beta-blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levodopa",
"       </td>",
"       <td>",
"        Antagonism of levodopa's hypotensive and positive inotropic effects",
"       </td>",
"       <td>",
"        Monitor for altered response; interaction may have favorable results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine",
"       </td>",
"       <td>",
"        Propranolol pretreatment increases lidocaine levels with potential toxicity",
"       </td>",
"       <td>",
"        Combination should be used with caution; use lower doses of lidocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyldopa",
"       </td>",
"       <td>",
"        Hypertension during stress",
"       </td>",
"       <td>",
"        Monitor for hypertensive episodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAO inhibitors",
"       </td>",
"       <td>",
"        Uncertain, theoretical",
"       </td>",
"       <td>",
"        Manufacturer of propranolol considers concurrent use contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenothazines",
"       </td>",
"       <td>",
"        Additive hypotensive effects",
"       </td>",
"       <td>",
"        Monitor for altered response, especially with high doses of phenothiazines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylpropranolamine",
"       </td>",
"       <td>",
"        Severe hypertensive reaction",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Additive cardiac depressant effects",
"       </td>",
"       <td>",
"        Administer IV phenytoin with great caution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"       <td>",
"        Additive cardiac depressant effects",
"       </td>",
"       <td>",
"        Observe patient's response; few patient show ill effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reserpine",
"       </td>",
"       <td>",
"        Excessive sympathetic blockade",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        Increased metabolism of&nbsp;beta-blockers",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking",
"       </td>",
"       <td>",
"        Increased metabolism of&nbsp;beta-blockers",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"       <td>",
"        Inhibits negative inotropic and chronotropic effects of&nbsp;beta-blockers",
"       </td>",
"       <td>",
"        Observe patient's response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tubocurarine",
"       </td>",
"       <td>",
"        Enhanced neuromuscular blockade",
"       </td>",
"       <td>",
"        Observe response in surgical patients, especially after high doses of propranolol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30861=[""].join("\n");
var outline_f30_8_30861=null;
var title_f30_8_30862="Spiral fracture of the middle phalanx";
var content_f30_8_30862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spiral fracture of the middle phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30862=[""].join("\n");
var outline_f30_8_30862=null;
var title_f30_8_30863="Mitral stenosis M mode";
var content_f30_8_30863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50915/mmodemst_conv.mp4?title=Mitral+stenosis+M+mode\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram shows severely limited movement of the anterior mitral leaflet which is also thickened. The E-F slope is markedly reduced and the A wave is absent, suggesting significant mitral stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_8_30863=[""].join("\n");
var outline_f30_8_30863=null;
